<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="21985d1b-08dc-46d3-b8ed-ef43c96a88cd"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use EFAVIRENZ TABLETS safely and effectively. See full prescribing information for EFAVIRENZ TABLETS.<br/>
      <br/>EFAVIRENZ tablets, for oral use<br/>Initial U.S. Approval: 1998</title>
   <effectiveTime value="20231213"/>
   <setId root="88dae33c-08d5-466f-8938-a0ae6b6bf388"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="650738743" root="1.3.6.1.4.1.519.1"/>
            <name>Strides Pharma Science Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="918513263" root="1.3.6.1.4.1.519.1"/>
                        <name>Strides Pharma Science Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64380-705" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64380-705" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64380-705" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="6230fa8d-6315-41aa-8a79-d0a0cd89718d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20231213"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64380-705" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Efavirenz<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Efavirenz</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="600" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JE6H2O27P8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EFAVIRENZ</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JE6H2O27P8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EFAVIRENZ</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UKE75GEA7F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (90000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64380-705-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250525"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA078509" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250525"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">EFZ</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID4">
               <id root="e91c7e38-b8e9-46a1-8201-0fe1979b4a10"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID8">Efavirenz in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.</paragraph>
               </text>
               <effectiveTime value="20200908"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID6">Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID9">
               <id root="f34765be-6da5-4c8c-a329-ab54ce699b76"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20231214"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID11" styleCode="Disc">
                           <item>Efavirenz tablets USP should be taken orally once daily on an empty stomach, preferably at bedtime. (2)</item>
                           <item>Recommended adult dose: 600 mg. (2.2)</item>
                           <item>With voriconazole, increase voriconazole maintenance dose to 400 mg every 12 hours and decrease efavirenz dose to 300 mg once daily using the capsule formulation. (2.2)</item>
                           <item>With rifampin, increase Efavirenz dose to 800 mg once daily for patients weighing 50 kg or more. (2.2)</item>
                           <item>Pediatric dosing is based on weight. (2.3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID12">
                     <id root="d841245b-873b-4e68-b64c-084b91e17730"/>
                     <title>2.1 Hepatic Function</title>
                     <text>
                        <paragraph ID="ID13">Monitor hepatic function prior to and during treatment with Efavirenz <content styleCode="italics">[see Warnings and Precautions (5.9)].</content>
                        </paragraph>
                        <paragraph>Efavirenz is not recommended in patients with moderate or severe hepatic impairment (Child Pugh B or C) <content styleCode="italics">[see Warnings and Precautions (5.9) and Use in Specific Populations (8.6)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID14">
                     <id root="f9cc2952-c160-471f-9160-4419f2f1c626"/>
                     <title>2.2 Adults</title>
                     <text>
                        <paragraph ID="ID15">The recommended dosage of efavirenz is 600 mg orally, once daily, in combination with a protease inhibitor and/or nucleoside analogue reverse transcriptase inhibitors (NRTIs). It is recommended that efavirenz be taken on an empty stomach, preferably at bedtime. The increased efavirenz concentrations observed following administration of efavirenz with food may lead to an increase in frequency of adverse reactions <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. Dosing at bedtime may improve the tolerability of nervous system symptoms <content styleCode="italics">[see Warnings and Precautions (5.6) Adverse Reactions (6.1), and Patient Counseling Information (17)]</content>. Efavirenz Tablets 600 mg should be swallowed intact with liquid. For patients who cannot swallow tablets, the capsule sprinkle method of administration is recommended <content styleCode="italics">[see Dosage and Administration (2.4)]</content>.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Concomitant Antiretroviral Therapy </paragraph>
                        <paragraph>Efavirenz must be given in combination with other antiretroviral medications <content styleCode="italics">[see Indications and Usage (1), Warnings and Precautions (5.3) Drug Interactions (7.1), and Clinical Pharmacology (12.3)].</content> </paragraph>
                        <paragraph>Dosage Adjustment </paragraph>
                        <paragraph>If efavirenz is coadministered with voriconazole, the voriconazole maintenance dose should be increased to 400 mg every 12 hours and the efavirenz dose should be decreased to 300 mg once daily using the capsule formulation (one 200 mg and two 50 mg capsules or six 50 mg capsules).Efavirenz tablets must not be broken <content styleCode="italics">[see Drug Interactions (7.1, Table 5) and Clinical Pharmacology (12.3, Tables 7 and 8)]. </content>
                        </paragraph>
                        <paragraph>If Efavirenz is coadministered with rifampin to patients weighing 50 kg or more, an increase in the dose of Efavirenz to 800 mg once daily is recommended <content styleCode="italics">[see Drug Interactions (7.1, Table 5) and Clinical Pharmacology (12.3, Table 8)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID16">
                     <id root="feb63396-cbad-4b40-8a93-d5df81f66521"/>
                     <title>2.3 Pediatric Patients</title>
                     <text>
                        <paragraph ID="ID17">It is recommended that efavirenz be taken on an empty stomach, preferably at bedtime. Table 1 describes the recommended dose of efavirenz for pediatric patients 3 months of age or older and weighing between 3.5 kg and 40 kg <content styleCode="italics">[see Clinical Pharmacology (12.3)].</content> The recommended dosage of efavirenz for pediatric patients weighing 40 kg or greater is 600 mg once daily. For pediatric patients who cannot swallow capsules, the capsule contents can be administered with a small amount of food or infant formula using the capsule sprinkle method of administration <content styleCode="italics">[see Dosage and Administration (2.4)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Efavirenz Dosing in Pediatric Patients</content>
                        </paragraph>
                        <table ID="ID18" width="100%" styleCode="Noautorules">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup>Capsules can be administered intact or as sprinkles <content styleCode="italics">[see Dosage and Administration (2.4) ].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup>Tablets must not be crushed</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Patient Body Weight</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Efavirenz  Daily Dose</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Number of Capsules</content>
                                    <sup>a</sup>
                                    <content styleCode="bold">  or Tablets</content>
                                    <sup>b</sup>
                                    <content styleCode="bold">  and Strength to Administer</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 3.5 kg to less than 5 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 100 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> two 50 mg capsules<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 5 kg to less than 7.5 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 150 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> three 50 mg capsules<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 7.5 kg to less than 15 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 200 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> one 200 mg capsule<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 15 kg to less than 20 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 250 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> one 200 mg + one 50 mg capsule<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 20 kg to less than 25 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 300 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> one 200 mg + two 50 mg capsules<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 25 kg to less than 32.5 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 350 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> one 200 mg + three 50 mg capsules<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 32.5 kg to less than 40 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> two 200 mg capsules<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> at least 40 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 600 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> one 600 mg tablet OR<br/>  three 200 mg capsules<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20231214"/>
                  </section>
               </component>
               <component>
                  <section ID="ID19">
                     <id root="95e2e693-c3c7-46f6-9f01-1020ef243176"/>
                     <title>2.4 Capsule Sprinkle Method of Administration</title>
                     <text>
                        <paragraph ID="ID20">For pediatric patients at least 3 months old and weighing at least 3.5 kg and adults who cannot swallow capsules or tablets, the capsule contents may be administered with a small amount (1 to 2 teaspoons) of food. Use of infant formula for mixing should only be considered for those young infants who cannot reliably consume solid foods. Patients and caregivers should be instructed to open the capsule carefully to avoid spillage or dispersion of the capsule contents into the air. The capsule should be held horizontally over a small container and carefully twisted to open. For patients able to tolerate solid foods, the entire capsule contents should be gently mixed with an age-appropriate soft food, such as applesauce, grape jelly, or yogurt, in the small container. For young infants receiving the capsule sprinkle-infant formula mixture, the entire capsule contents should be gently mixed into 2 teaspoons of reconstituted room temperature infant formula in a small container by carefully stirring with a small spoon, and then drawing up the mixture into a 10 mL oral dosing syringe for administration. After administration of the efavirenz-food or –formula mixture, an additional small amount (approximately 2 teaspoons) of food or formula must be added to the empty mixing container, stirred to disperse any remaining efavirenz residue, and administered to the patient. The efavirenz-food or -formula mixture should be administered within 30 minutes of mixing. No additional food should be consumed for 2 hours after administration of efavirenz.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID21">
               <id root="f2de3839-0449-4ea9-b7de-8c17df497dfd"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" ID="ID25" styleCode="Disc">
                     <item>Tablets</item>
                  </list>
                  <paragraph ID="ID26">   Efavirenz tablets, 600 mg are off white coloured, capsule shaped, film coated tablets imprinted with "EFZ" on one side and plain on other side.</paragraph>
               </text>
               <effectiveTime value="20200908"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID23" styleCode="Disc">
                           <item>Tablets:      600 mg. (3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID27">
               <id root="31d615c3-482a-40a4-9bd2-53ef6820c4f4"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered" ID="ID28" styleCode="Disc">
                     <item>Efavirenz is contraindicated in patients with previously      demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson      syndrome, erythema multiforme, or toxic skin eruptions) to      any of the      components of this product.</item>
                     <item>Coadministration of efavirenz with      elbasvir and grazoprevir is contraindicated <content styleCode="italics">[see Warnings and      Precautions (5.1) and Drug Interactions (7.1)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231213"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID30" styleCode="Disc">
                           <item>Patients with previously demonstrated      hypersensitivity (e.g.,      Stevens-Johnson syndrome, erythema multiforme, or      toxic skin      eruptions) to any of the components of this product.      (4)</item>
                           <item>Coadministration of efavirenz with      elbasvir/grazoprevir.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID31">
               <id root="f825cdbb-221a-4a3a-a207-1e3ad9c00acb"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20231213"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID33" styleCode="Disc">
                           <item>
                              <content styleCode="italics">QTc prolongation:</content>Consider      alternatives to Efavirenz in patients taking other medications with a      known risk of Torsade de Pointes or in patients at higher risk of Torsade      de Pointes. (5.2)</item>
                           <item>
                              <content styleCode="italics">Do not use as a single agent</content>or add on as a sole agent to a failing regimen. Consider      potential for cross resistance when choosing other agents. (5.3)</item>
                           <item>Not recommended with ATRIPLA, which      contains efavirenz, emtricitabine, and tenofovir disoproxil fumarate,      unless needed for dose adjustment when coadministered with rifampin. (5.4)</item>
                           <item>
                              <content styleCode="italics">Serious psychiatric symptoms:</content>Immediate medical evaluation is recommended for serious      psychiatric symptoms such as severe depression or suicidal ideation.      (5.5,17)</item>
                           <item>
                              <content styleCode="italics">Nervous system symptoms (NSS):</content>NSS are frequent and usually begin 1-2 days after initiating      therapy and resolve in 2-4 weeks. Dosing at bedtime may improve      tolerability. NSS are not predictive of onset of psychiatric symptoms.      (5.6, 6.1, 17)</item>
                           <item>
                              <content styleCode="italics">Embryo-Fetal Toxicity:</content>Avoid administration in the first trimester of pregnancy as      fetal harm may occur. (5.7, 8.1)</item>
                           <item>
                              <content styleCode="italics">Hepatotoxicity:</content>Monitor liver function tests before and during treatment in      patients with underlying hepatic disease, including hepatitis B or C      coinfection, marked transaminase elevations, or who are taking medications      associated with liver toxicity. Among reported cases of hepatic failure, a      few occurred in patients with no pre-existing hepatic disease. (5.9, 6.1,      8.6)</item>
                           <item>
                              <content styleCode="italics">Rash:</content>Rash      usually begins within 1-2 weeks after initiating therapy and resolves      within 4 weeks. Discontinue if severe rash develops. (5.8, 6.1, 17)</item>
                           <item>
                              <content styleCode="italics">Convulsions:</content>Use caution in patients with a history of seizures. (5.10)</item>
                           <item>
                              <content styleCode="italics">Lipids:</content>Total cholesterol and triglyceride elevations. Monitor before therapy and      periodically thereafter. (5.11)</item>
                           <item>
                              <content styleCode="italics">Immune reconstitution syndrome:</content>May necessitate further evaluation and treatment. (5.12)</item>
                           <item>
                              <content styleCode="italics">Redistribution/accumulation of body      fat:</content>Observed in patients receiving      antiretroviral therapy. (5.13,17)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID34">
                     <id root="8f65e178-daf8-48c5-b216-53e6dc6c8783"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>5.1 Drug Interactions</title>
                     <text>
                        <paragraph ID="ID35">Efavirenz plasma concentrations may be altered by substrates, inhibitors, or inducers of CYP3A. Likewise, efavirenz may alter plasma concentrations of drugs metabolized by CYP3A or CYP2B6. The most prominent effect of efavirenz at steady state is induction of CYP3A and CYP2B6<content styleCode="italics"> [see Dosage and Administration (2.2) and Drug Interactions (7.1)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID36">
                     <id root="c076c403-7dd4-46d0-a68c-bad65d035212"/>
                     <title>5.2 QTc Prolongation</title>
                     <text>
                        <paragraph ID="ID37">QTc prolongation has been observed with the use of efavirenz <content styleCode="italics">[see</content> <content styleCode="italics">Drug Interactions (7.3, 7.4) </content>and <content styleCode="italics">Clinical Pharmacology (12.2)]. </content>Consider alternatives to efavirenz when coadministered with a drug with a known risk of Torsade de Pointes or when administered to patients at higher risk of Torsade de Pointes.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID38">
                     <id root="53bc7d31-d93e-487d-974a-9ced24e70c78"/>
                     <title>5.3 Resistance</title>
                     <text>
                        <paragraph ID="ID39">Efavirenz must not be used as a single agent to treat HIV-1 infection or added on as a sole agent to a failing regimen. Resistant virus emerges rapidly when efavirenz is administered as monotherapy. The choice of new antiretroviral agents to be used in combination with efavirenz should take into consideration the potential for viral cross-resistance.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID40">
                     <id root="ee280438-e0bb-490d-a6e2-f94dfa5a54ed"/>
                     <title>5.4 Coadministration with Related Products</title>
                     <text>
                        <paragraph ID="ID41">Coadministration of Efavirenz with ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is not recommended unless needed for dose adjustment (e.g., with rifampin), since efavirenz is one of its active ingredients.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID42">
                     <id root="9e9ce75d-396e-4ae4-af70-af709fce2e30"/>
                     <title>5.5 Psychiatric Symptoms</title>
                     <text>
                        <paragraph ID="ID43">Serious psychiatric adverse experiences have been reported in patients treated with Efavirenz. In controlled trials of 1008 patients treated with regimens containing efavirenz for a mean of 2.1 years and 635 patients treated with control regimens for a mean of 1.5 years, the frequency (regardless of causality) of specific serious psychiatric events among patients who received Efavirenz or control regimens, respectively, were severe depression (2.4%, 0.9%), suicidal ideation (0.7%, 0.3%), nonfatal suicide attempts (0.5%, 0), aggressive behavior (0.4%, 0.5%), paranoid reactions (0.4%, 0.3%), and manic reactions (0.2%, 0.3%). When psychiatric symptoms similar to those noted above were combined and evaluated as a group in a multifactorial analysis of data from Study 006, treatment with efavirenz was associated with an increase in the occurrence of these selected psychiatric symptoms. Other factors associated with an increase in the occurrence of these psychiatric symptoms were history of injection drug use, psychiatric history, and receipt of psychiatric medication at study entry; similar associations were observed in both the Efavirenz and control treatment groups. In Study 006, onset of new serious psychiatric symptoms occurred throughout the study for both Efavirenz-treated and control-treated patients. One percent of Efavirenz-treated patients discontinued or interrupted treatment because of one or more of these selected psychiatric symptoms. There have also been occasional postmarketing reports of death by suicide, delusions, and psychosis-like behavior although a causal relationship to the use of Efavirenz cannot be determined from these reports. Postmarketing cases of catatonia have also been reported and may be associated with increased efavirenz exposure. Patients with serious psychiatric adverse experiences should seek immediate medical evaluation to assess the possibility that the symptoms may be related to the use of Efavirenz, and if so, to determine whether the risks of continued therapy outweigh the benefits <content styleCode="italics">[see Adverse Reactions (6.1)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID44">
                     <id root="9f66f573-9923-4e79-85b8-2281563074a5"/>
                     <title>5.6 Nervous System Symptoms</title>
                     <text>
                        <paragraph ID="ID45">Fifty-three percent (531/1008) of patients receiving Efavirenz in controlled trials reported central nervous system symptoms (any grade, regardless of causality) compared to 25% (156/635) of patients receiving control regimens <content styleCode="italics">[see Adverse Reactions (6.1, Table 3)].</content> These symptoms included, but were not limited to, dizziness (28.1% of the 1008 patients), insomnia (16.3%), impaired concentration (8.3%), somnolence (7.0%), abnormal dreams (6.2%), and hallucinations (1.2%). These symptoms were severe in 2.0% of patients, and 2.1% of patients discontinued therapy as a result. These symptoms usually begin during the first or second day of therapy and generally resolve after the first 2-4 weeks of therapy. After 4 weeks of therapy, the prevalence of nervous system symptoms of at least moderate severity ranged from 5% to 9% in patients treated with regimens containing Efavirenz and from 3% to 5% in patients treated with a control regimen. Patients should be informed that these common symptoms were likely to improve with continued therapy and were not predictive of subsequent onset of the less frequent psychiatric symptoms <content styleCode="italics">[see Warnings and Precautions (5.5)].</content> Dosing at bedtime may improve the tolerability of these nervous system symptoms <content styleCode="italics">[see Dosage and Administration (2)].</content>
                        </paragraph>
                        <paragraph>Analysis of long-term data from Study 006 (median follow-up 180 weeks, 102 weeks, and 76 weeks for patients treated with Efavirenz + zidovudine + lamivudine, Efavirenz + indinavir, and indinavir + zidovudine + lamivudine, respectively) showed that, beyond 24 weeks of therapy, the incidences of new-onset nervous system symptoms among Efavirenz-treated patients were generally similar to those in the indinavir-containing control arm.</paragraph>
                        <paragraph>Late-onset neurotoxicity, including ataxia and encephalopathy (impaired consciousness, confusion, psychomotor slowing, psychosis, delirium), may occur months to years after beginning efavirenz therapy. Some events of late-onset neurotoxicity have occurred in patients with CYP2B6 genetic polymorphisms which are associated with increased efavirenz levels despite standard dosing of Efavirenz. Patients presenting with signs and symptoms of serious neurologic adverse experiences should be evaluated promptly to assess the possibility that these events may be related to efavirenz use, and whether discontinuation of Efavirenz is warranted. </paragraph>
                        <paragraph>Patients receiving Efavirenz should be alerted to the potential for additive central nervous system effects when Efavirenz is used concomitantly with alcohol or psychoactive drugs.</paragraph>
                        <paragraph>Patients who experience central nervous system symptoms such as dizziness, impaired concentration, and/or drowsiness should avoid potentially hazardous tasks such as driving or operating machinery.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID46">
                     <id root="a4474934-dd8d-4947-8911-5cf1cf61d09a"/>
                     <title>5.7 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph ID="ID47">Efavirenz may cause fetal harm when administered during the first trimester to a pregnant woman. Advise females of reproductive potential who are receiving Efavirenz to avoid pregnancy <content styleCode="italics">[see Use in Specific Populations (8.1 and 8.3)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID48">
                     <id root="57defa46-7b47-4cb5-b04f-de440bd0c04b"/>
                     <title>5.8 Rash</title>
                     <text>
                        <paragraph ID="ID49">In controlled clinical trials, 26% (266/1008) of adult patients treated with 600 mg Efavirenz experienced new-onset skin rash compared with 17% (111/635) of those treated in control groups <content styleCode="italics">[see Adverse Reactions (6.1)].</content> Rash associated with blistering, moist desquamation, or ulceration occurred in 0.9% (9/1008) of patients treated with Efavirenz. The incidence of Grade 4 rash (e.g., erythema multiforme, Stevens-Johnson syndrome) in adult patients treated with Efavirenz in all studies and expanded access was 0.1%. Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 2 weeks of initiating therapy with efavirenz (median time to onset of rash in adults was 11 days) and, in most patients continuing therapy with efavirenz, rash resolves within 1 month (median duration, 16 days). The discontinuation rate for rash in adult clinical trials was 1.7% (17/1008). </paragraph>
                        <paragraph>Rash was reported in 59 of 182 pediatric patients (32%) treated with Efavirenz <content styleCode="italics">[see Adverse Reactions (6.2)].</content> Two pediatric patients experienced Grade 3 rash (confluent rash with fever, generalized rash), and four patients had Grade 4 rash (erythema multiforme). The median time to onset of rash in pediatric patients was 28 days (range 3-1642 days). Prophylaxis with appropriate antihistamines before initiating therapy with Efavirenz in pediatric patients should be considered.</paragraph>
                        <paragraph>Efavirenz can generally be reinitiated in patients interrupting therapy because of rash. Efavirenz should be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement, or fever. Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. For patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome), alternative therapy should be considered <content styleCode="italics">[see Contraindications (4)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID50">
                     <id root="3ebdc41a-98e4-4d52-a20c-1f9f5cdabd15"/>
                     <title>5.9 Hepatotoxicity</title>
                     <text>
                        <paragraph ID="ID51">Postmarketing cases of hepatitis, including fulminant hepatitis progressing to liver failure requiring transplantation or resulting in death, have been reported in patients treated with Efavirenz. Reports have included patients with underlying hepatic disease, including coinfection with hepatitis B or C, and patients without pre-existing hepatic disease or other identifiable risk factors.</paragraph>
                        <paragraph>Efavirenz is not recommended for patients with moderate or severe hepatic impairment. Careful monitoring is recommended for patients with mild hepatic impairment receiving Efavirenz <content styleCode="italics">[see Adverse Reactions (6.1) and</content> <content styleCode="italics">Use in Specific Populations (8.6)].</content>
                        </paragraph>
                        <paragraph>Monitoring of liver enzymes before and during treatment is recommended for all patients <content styleCode="italics">[see Dosage and Administration (2.1)]. </content>Consider discontinuing Efavirenz in patients with persistent elevations of serum transaminases to greater than five times the upper limit of the normal range. </paragraph>
                        <paragraph>Discontinue Efavirenz if elevation of serum transaminases is accompanied by clinical signs or symptoms of hepatitis or hepatic decompensation.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID52">
                     <id root="07db2419-f652-4254-b8f3-deaeed311a5d"/>
                     <title>5.10 Convulsions</title>
                     <text>
                        <paragraph ID="ID53">Convulsions have been observed in adult and pediatric patients receiving efavirenz, generally in the presence of known medical history of seizures <content styleCode="italics">[see Nonclinical Toxicology (13.2)].</content> Caution should be taken in any patient with a history of seizures. Patients who are receiving concomitant anticonvulsant medications primarily metabolized by the liver, such as phenytoin and phenobarbital, may require periodic monitoring of plasma levels <content styleCode="italics">[see Drug Interactions (7.1)].</content> </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID54">
                     <id root="7f32bc57-9095-4b86-bac0-c5081e4fe168"/>
                     <title>5.11 Lipid Elevations</title>
                     <text>
                        <paragraph ID="ID55">Treatment with Efavirenz has resulted in increases in the concentration of total cholesterol and triglycerides <content styleCode="italics">[see Adverse Reactions (6.1)].</content> Cholesterol and triglyceride testing should be performed before initiating Efavirenz therapy and at periodic intervals during therapy.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID56">
                     <id root="5acd3cdd-30a9-4a4a-a1aa-c88cc071b719"/>
                     <title>5.12 Immune Reconstitution Syndrome</title>
                     <text>
                        <paragraph ID="ID57">Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including Efavirenz. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as <content styleCode="italics">Mycobacterium avium</content> infection, cytomegalovirus, <content styleCode="italics">Pneumocystis jirovecii </content>pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.</paragraph>
                        <paragraph>Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-Barre syndrome and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID58">
                     <id root="23ac1856-7ac4-46a0-88a8-28c1d950aad7"/>
                     <title>5.13 Fat Redistribution</title>
                     <text>
                        <paragraph ID="ID59">Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID60">
               <id root="c91996ac-05a9-46bc-b117-5911cb1b37f4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID61">The most significant adverse reactions observed in patients treated with Efavirenz are:</paragraph>
                  <list listType="unordered" ID="ID62" styleCode="Disc">
                     <item>psychiatric symptoms <content styleCode="italics">[see Warnings and Precautions (5.5)]</content>
                     </item>
                     <item>nervous system symptoms <content styleCode="italics">[see Warnings      and Precautions (5.6)]</content>
                     </item>
                     <item>rash <content styleCode="italics">[see Warnings and Precautions      (5.8)]</content>
                     </item>
                     <item>hepatotoxicity <content styleCode="italics">[see Warnings and      Precautions (5.9)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231213"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID64">Most common adverse reactions (&gt;5%, moderate-severe) are impaired concentration, abnormal dreams, rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting. (6)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Strides Pharma Inc. at 1-877-244-9825 or go to www.strides.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID65">
                     <id root="b6b80bf8-b03f-4cd8-a101-2e109dc91d00"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID66">Because clinical studies are conducted under widely varying conditions, the adverse reaction rates reported cannot be directly compared to rates in other clinical studies and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>Adverse Reactions in Adults</paragraph>
                        <paragraph>The most common (&gt;5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with Efavirenz in combination with zidovudine/lamivudine or indinavir were rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting.</paragraph>
                        <paragraph>Selected clinical adverse reactions of moderate or severe intensity observed in ≥2% of Efavirenz-treated patients in two controlled clinical trials are presented in Table 2.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Selected Treatment-Emergent<sup>a</sup> Adverse Reactions of Moderate or Severe Intensity Reported in ≥2% of Efavirenz-Treated Patients in Studies 006 and ACTG 364</content>
                        </paragraph>
                        <table ID="ID67" width="143%" styleCode="Noautorules">
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>a </sup>Includes adverse events at least possibly related to study drug or of unknown relationship for Study 006. Includes all adverse events regardless of relationship to study drug for Study ACTG 364. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Efavirenz provided as 600 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> Median duration of treatment.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>d</sup> Includes erythema multiforme, rash, rash erythematous, rash follicular, rash maculopapular, rash petechial, rash pustular, and urticaria for Study 006 and macules, papules, rash, erythema, redness, inflammation, allergic rash, urticaria, welts, hives, itchy, and pruritus for ACTG 364.  </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">— = Not Specified.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">ZDV = zidovudine, LAM=lamivudine</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="bottom" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reactions</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule" align="center">
                                    <content styleCode="bold"> Study 006 LAM-, NNRTI-, and Protease</content>
                                    <br/>
                                    <content styleCode="bold"> Inhibitor-Naive Patients</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Study ACTG 364</content>
                                    <br/>
                                    <content styleCode="bold"> NRTI-experienced, NNRTI-, and</content>
                                    <br/>
                                    <content styleCode="bold"> Protease Inhibitor-Naive Patients</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="center">  Efavirenz<sup>b</sup>
                                    <br/> +<br/>  ZDV/LAM<br/>  (n=412)<br/>  180 weeks<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="center">  Efavirenz<sup>b</sup>
                                    <br/> +<br/>  Indinavir<br/>  (n=415)<br/>  102 weeks<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="center">  Indinavir<br/>  +<br/>  ZDV/LAM<br/>  (n=401)<br/>  76 weeks<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center">  Efavirenz<sup>b</sup>
                                    <br/> + Nelfinavir<br/>  + NRTIs<br/>  (n=64)<br/>  71.1 weeks<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center">
                                    <content styleCode="bold">  Efavirenz<sup>b</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> +</content>
                                    <br/>
                                    <content styleCode="bold">  NRTIs</content>
                                    <br/>
                                    <content styleCode="bold">  (n=65)</content>
                                    <br/>
                                    <content styleCode="bold">  70.9</content>
                                    <br/>
                                    <content styleCode="bold">   weeks<sup>c</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold">  Nelfinavir</content>
                                    <br/>
                                    <content styleCode="bold">  +</content>
                                    <br/>
                                    <content styleCode="bold">  NRTIs</content>
                                    <br/>
                                    <content styleCode="bold">  (n=66)</content>
                                    <br/>
                                    <content styleCode="bold">  62.7 weeks<sup>c</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">
                                    <content styleCode="bold">  Body as a Whole</content>
                                    <br/>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Fatigue<br/>
                                 </td>
                                 <td valign="top" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 9%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Pain<br/>
                                 </td>
                                 <td valign="top" align="center"> 1%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" align="center"> 13%<br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 17%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">
                                    <content styleCode="bold">  Central and Peripheral </content>
                                    <br/>
                                    <content styleCode="bold">  Nervous System</content>
                                    <br/>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Dizziness<br/>
                                 </td>
                                 <td valign="top" align="center"> 9%<br/>
                                 </td>
                                 <td valign="top" align="center"> 9%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Headache<br/>
                                 </td>
                                 <td valign="top" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Insomnia<br/>
                                 </td>
                                 <td valign="top" align="center"> 7%<br/>
                                 </td>
                                 <td valign="top" align="center"> 7%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Concentration<br/>  impaired<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> &lt;1%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Abnormal<br/>  dreams<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> 1%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> —<br/>
                                 </td>
                                 <td valign="top" align="center"> —<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> —<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Somnolence<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> &lt;1%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Anorexia<br/>
                                 </td>
                                 <td valign="top" align="center"> 1%<br/>
                                 </td>
                                 <td valign="top" align="center"> &lt;1%<br/>
                                 </td>
                                 <td valign="top" align="center"> &lt;1%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">
                                    <content styleCode="bold">  Gastrointestinal</content>
                                    <br/>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Nausea<br/>
                                 </td>
                                 <td valign="top" align="center"> 10%<br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" align="center"> 24%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Vomiting<br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> 14%<br/>
                                 </td>
                                 <td valign="top" align="center"> —<br/>
                                 </td>
                                 <td valign="top" align="center"> —<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> —<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Diarrhea<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" align="center"> 14%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 9%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Dyspepsia<br/>
                                 </td>
                                 <td valign="top" align="center"> 4%<br/>
                                 </td>
                                 <td valign="top" align="center"> 4%<br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Abdominal pain<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">
                                    <content styleCode="bold">  Psychiatric</content>
                                    <br/>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Anxiety<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 4%<br/>
                                 </td>
                                 <td valign="top" align="center"> &lt;1%<br/>
                                 </td>
                                 <td valign="top" align="center"> —<br/>
                                 </td>
                                 <td valign="top" align="center"> —<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> —<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Depression<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 4%<br/>
                                 </td>
                                 <td valign="top" align="center"> &lt;1%<br/>
                                 </td>
                                 <td valign="top" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Nervousness<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">
                                    <content styleCode="bold">  Skin &amp; Appendages</content>
                                    <br/>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">  Rash<sup>d </sup>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center"> 11%<br/>
                                 </td>
                                 <td valign="top" align="center"> 16%<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" align="center"> 9%<br/>
                                 </td>
                                 <td valign="top" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 9%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left"> Pruritus<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> &lt;1%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 1%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 1%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 9%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 9%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID68">Pancreatitis has been reported, although a causal relationship with efavirenz has not been established. Asymptomatic increases in serum amylase levels were observed in a significantly higher number of patients treated with efavirenz 600 mg than in control patients <content styleCode="italics">(</content>see<content styleCode="italics"> Laboratory Abnormalities).</content>
                        </paragraph>
                        <paragraph>Nervous System Symptoms</paragraph>
                        <paragraph>For 1008 patients treated with regimens containing Efavirenz and 635 patients treated with a control regimen in controlled trials, Table 3 lists the frequency of symptoms of different degrees of severity and gives the discontinuation rates for one or more of the following nervous system symptoms: dizziness, insomnia, impaired concentration, somnolence, abnormal dreaming, euphoria, confusion, agitation, amnesia, hallucinations, stupor, abnormal thinking, and depersonalization <content styleCode="italics">[</content>see <content styleCode="italics">Warnings and Precautions (5.6)]. </content>The frequencies of specific central and peripheral nervous system symptoms are provided in Table 2.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3: Percent of Patients with One or More Selected Nervous System Symptoms<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <table ID="ID69" width="100%" styleCode="Noautorules">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> Includes events reported regardless of causality.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Data from Study 006 and three Phase 2/3 studies.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> "Mild" = Symptoms which do not interfere with patient's daily activities.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>d</sup> "Moderate" = Symptoms which may interfere with daily activities.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>e</sup> "Severe" = Events which interrupt patient's usual daily activities.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Percent of Patients with:</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="center">
                                    <content styleCode="bold">  Efavirenz 600 mg Once</content>
                                    <br/>
                                    <content styleCode="bold">  Daily (n=1008)</content>
                                    <br/>
                                    <content styleCode="bold">  %</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Control Groups</content>
                                    <br/>
                                    <content styleCode="bold">  (n=635)</content>
                                    <br/>
                                    <content styleCode="bold">  %</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Symptoms of any severity<br/>
                                 </td>
                                 <td valign="top" align="center"> 52.7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 24.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">  Mild symptoms<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center"> 33.3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 15.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">  Moderate symptoms<sup>d </sup>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center"> 17.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 7.7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">  Severe symptoms<sup>e</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center"> 2.0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 1.3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left"> Treatment discontinuation as a result of symptoms<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 2.1<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID70">Psychiatric Symptoms</paragraph>
                        <paragraph>Serious psychiatric adverse experiences have been reported in patients treated with Efavirenz. In controlled trials, psychiatric symptoms observed at a frequency greater than 2% among patients treated with Efavirenz or control regimens, respectively, were depression (19%, 16%), anxiety (13%, 9%), and nervousness (7%, 2%).</paragraph>
                        <paragraph>Rash</paragraph>
                        <paragraph>In controlled clinical trials, the frequency of rash (all grades, regardless of causality) was 26 % for 1008 adults treated with regimens containing Efavirenz and 17% for 635 adults treated with a control regimen. Most reports of rash were mild or moderate in severity. The frequency of Grade 3 rash was 0.8% for Efavirenz-treated patients and 0.3% for control groups, and the frequency of Grade 4 rash was 0.1% for Efavirenz and 0 for control groups. The discontinuation rates as a result of rash were 1.7% for Efavirenz-treated patients and 0.3% for control groups <content styleCode="italics">[see Warnings and Precautions (5.8)].</content>
                        </paragraph>
                        <paragraph>Experience with Efavirenz in patients who discontinued other antiretroviral agents of the NNRTI class is limited. Nineteen patients who discontinued nevirapine because of rash have been treated with Efavirenz. Nine of these patients developed mild-to-moderate rash while receiving therapy with Efavirenz, and two of these patients discontinued because of rash.</paragraph>
                        <paragraph>Laboratory Abnormalities</paragraph>
                        <paragraph>Selected Grade 3-4 laboratory abnormalities reported in ≥ 2% of Efavirenz-treated patients in two clinical trials are presented in Table 4.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4: Selected Grade 3-4 Laboratory Abnormalities Reported in ≥2% of Efavirenz-Treated Patients in Studies 006 and ACTG 364</content>
                        </paragraph>
                        <table ID="ID71" width="143%" styleCode="Noautorules">
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="8">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> Efavirenz provided as 600 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Median duration of treatment.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> Isolated elevations of GGT in patients receiving efavirenz may reflect enzyme induction not associated with liver toxicity.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8">
                                    <paragraph styleCode="Footnote">
                                       <sup>d</sup> Nonfasting.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8">
                                    <paragraph styleCode="Footnote">ZDV = zidovudine, LAM = lamivudine, ULN = upper limit of normal, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyltransferase.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Study 006</content>
                                    <br/>
                                    <content styleCode="bold">  LAM- NNRTI-, and Protease Inhibitor-Naive Patients</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Study ACTG 364 NRTI-experienced,</content>
                                    <br/>
                                    <content styleCode="bold">  NNRTI-, and Protease</content>
                                    <br/>
                                    <content styleCode="bold">  Inhibitor-Naive Patients</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center">  Variable<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  Limit<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  Efavirenz<sup>a </sup>+ ZDV/LAM<br/>  (n=412)<br/>  180 weeks<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  Efavirenz<sup>a</sup> + Indinavir<br/>  (n=415)<br/>  102 weeks<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  Indinavir +<br/>  ZDV/LAM<br/>  (n=401)<br/>  76 weeks<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  Efavirenz<sup>a</sup> + Nelfinavir<br/>  + NRTIs<br/>  (n=64)<br/>  71.1 weeks<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  Efavirenz<sup>a</sup> + NRTIs<br/>  (n=65)<br/>  70.9 weeks<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  Nelfinavir<br/>  + NRTIs<br/>  (n=66)<br/>  62.7 weeks<sup>b</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left"> Chemistry<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> ALT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &gt;5 x ULN<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> AST<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &gt;5 x ULN<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center">  GGT<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &gt;5 x ULN<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Amylase<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &gt;2 x ULN<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Glucose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &gt;250 mg/dL<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center">  Triglycerides<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> ≥751 mg/dL<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 9%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 11%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 17%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="center"> Hematology<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Neutrophils<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">  &lt;750/mm<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID72">
                           <content styleCode="italics">Patients Coinfected with Hepatitis B or C</content>
                        </paragraph>
                        <paragraph>Liver function tests should be monitored in patients with a history of hepatitis B and/or C. In the long-term data set from Study 006, 137 patients treated with Efavirenz-containing regimens (median duration of therapy, 68 weeks) and 84 treated with a control regimen (median duration, 56 weeks) were seropositive at screening for hepatitis B (surface antigen positive) and/or C (hepatitis C antibody positive). Among these coinfected patients, elevations in AST to greater than five times ULN developed in 13% of patients in the Efavirenz arms and 7% of those in the control arm, and elevations in ALT to greater than five times ULN developed in 20% of patients in the Efavirenz arms and 7% of patients in the control arm. Among coinfected patients, 3% of those treated with Efavirenz-containing regimens and 2% in the control arm discontinued from the study because of liver or biliary system disorders <content styleCode="italics">[see Warnings and Precautions (5.9)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Lipids</content>
                        </paragraph>
                        <paragraph>Increases from baseline in total cholesterol of 10 - 20% have been observed in some uninfected volunteers receiving Efavirenz. In patients treated with Efavirenz + zidovudine + lamivudine, increases from baseline in nonfasting total cholesterol and HDL of approximately 20% and 25%, respectively, were observed. In patients treated with Efavirenz + indinavir, increases from baseline in nonfasting cholesterol and HDL of approximately 40% and 35%, respectively, were observed. Nonfasting total cholesterol levels ≥240 mg/dL and ≥300 mg/dL were reported in 34% and 9%, respectively, of patients treated with Efavirenz + zidovudine + lamivudine; 54% and 20%, respectively, of patients treated with Efavirenz + indinavir; and 28% and 4%, respectively, of patients treated with indinavir + zidovudine + lamivudine. The effects of Efavirenz on triglycerides and LDL in this study were not well characterized since samples were taken from nonfasting patients. The clinical significance of these findings is unknown <content styleCode="italics">[see Warnings and Precautions (5.11)].</content>
                        </paragraph>
                        <paragraph>Adverse Reactions in Pediatric Patients </paragraph>
                        <paragraph>Because clinical studies are conducted under widely varying conditions, the adverse reaction rates reported cannot be directly compared to rates in other clinical studies and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>Assessment of adverse reactions is based on three clinical trials in 182 HIV-1 infected pediatric patients (3 months to 21 years of age) who received Efavirenz in combination with other antiretroviral agents for a median of 123 weeks. The adverse reactions observed in the three trials were similar to those observed in clinical trials in adults except that rash was more common in pediatric patients (32% for all grades regardless of causality) and more often of higher grade (ie, more severe). Two (1.1%) pediatric patients experienced Grade 3 rash (confluent rash with fever, generalized rash), and four (2.2%) pediatric patients had Grade 4 rash (all erythema multiforme). Five pediatric patients (2.7%) discontinued from the study because of rash <content styleCode="italics">[see Warnings and Precautions (5.8)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID73">
                     <id root="abd5ea9b-21b8-4165-88c1-69599ceb57b0"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID74">The following adverse reactions have been identified during postapproval use of Efavirenz. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole: </content>allergic reactions, asthenia, redistribution/accumulation of body fat <content styleCode="italics">[see Warnings and Precautions (5.13)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Central and Peripheral Nervous System: </content>abnormal coordination, ataxia, encephalopathy, cerebellar coordination and balance disturbances, convulsions, hypoesthesia, paresthesia, neuropathy, tremor, vertigo</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine: </content>gynecomastia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal: </content>constipation, malabsorption </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular: </content>flushing, palpitations</paragraph>
                        <paragraph>
                           <content styleCode="italics">Liver and Biliary System: </content>hepatic enzyme increase, hepatic failure, hepatitis. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic and Nutritional: </content>hypercholesterolemia, hypertriglyceridemia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal: </content>arthralgia, myalgia, myopathy </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric: </content>aggressive reactions, agitation, delusions, emotional lability, mania, neurosis, paranoia, psychosis, suicide, catatonia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory: </content>dyspnea </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Appendages: </content>erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome</paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses: </content>abnormal vision, tinnitus</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID75">
               <id root="daf347da-9499-46b7-be1f-73dd1f44248d"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20231213"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID77" styleCode="Disc">
                           <item>Coadministration      of efavirenz can alter the      concentrations of other drugs and other      drugs may alter the concentrations      of efavirenz. The potential for      drug-drug interactions should be      considered before and during      therapy. (7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID78">
                     <id root="ac09eb39-d1b3-4a48-ab2f-aeec66931ef4"/>
                     <title>7.1 Potential for Efavirenz to Affect other Drugs</title>
                     <text>
                        <paragraph ID="ID79">Efavirenz has been shown <content styleCode="italics">in vivo</content> to induce CYP3A and CYP2B6. Other compounds that are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when coadministered with efavirenz.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID80">
                     <id root="91a9b0ba-a678-413c-bdf7-05819dfdfeb8"/>
                     <title>7.2 Potential for Other Drugs to Affect Efavirenz</title>
                     <text>
                        <paragraph ID="ID81">Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations <content styleCode="italics">[see Dosage and Administration (2.2)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID82">
                     <id root="8b5e2978-747a-4776-bf97-ff59f8b94b4d"/>
                     <title>7.3 QT Prolonging Drugs</title>
                     <text>
                        <paragraph ID="ID83">There is limited information available on the potential for a pharmacodynamic interaction between Efavirenz and drugs that prolong the QTc interval. QTc prolongation has been observed with the use of efavirenz <content styleCode="italics">[see Clinical Pharmacology (12.2)].</content> Consider alternatives to Efavirenz when coadministered with a drug with a known risk of Torsade de Pointes.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID84">
                     <id root="97df5221-92fc-4f63-95ac-827ced04eb22"/>
                     <title>7.4 Established and Other Potentially Significant Drug Interactions</title>
                     <text>
                        <paragraph ID="ID85">Drug interactions with Efavirenz are summarized in Table 5. For pharmacokinetics data, <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content> Tables 7 and 8. </paragraph>
                        <paragraph>This table includes potentially significant interactions, but is not all inclusive.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 5: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction</content>
                        </paragraph>
                        <table ID="ID86" width="143%" styleCode="Noautorules">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold">  Concomitant Drug</content>
                                    <br/>
                                    <content styleCode="bold">  Class: Drug Name</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold">  Effect</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold">  Clinical Comment</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left">
                                    <content styleCode="italics">HIV antiviral agents </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Protease inhibitor: <br/>  Fosamprenavir <br/>  Calcium<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ amprenavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Fosamprenavir (unboosted): Appropriate doses of the combinations with respect to safety and efficacy have not been established. <br/>  Fosamprenavir/ritonavir: An additional 100 mg/day (300 mg total) of ritonavir is recommended when efavirenz is administered with fosamprenavir/ ritonavir once daily. No change in the ritonavir dose is required when efavirenz is administered with fosamprenavir plus ritonavir twice daily.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Protease inhibitor: <br/>  Atazanavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ atazanavir*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="italics">Treatment-naive patients: </content>  When coadministered with efavirenz, the recommended dose of atazanavir is 400 mg with ritonavir 100 mg (together once daily with food) and efavirenz 600 mg (once daily on an empty stomach, preferably at bedtime). <br/>
                                    <content styleCode="italics">Treatment-experienced patients: </content>  Coadministration of efavirenz and atazanavir is not recommended. <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Protease inhibitor: <br/>  Indinavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ indinavir*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> The optimal dose of indinavir, when given in combination with efavirenz, is not known. Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Protease inhibitor: Lopinavir/ritonavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ lopinavir*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Lopinavir/ritonavir once daily dosing is not recommended when coadministered with Efavirenz. <br/>  The dose of lopinavir/ritonavir must be increased when coadministered with Efavirenz. See the lopinavir/ritonavir prescribing information for dose adjustments of lopinavir/ritonavir when coadministered with efavirenz in adult and pediatric patients.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Protease inhibitor: Ritonavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↑ ritonavir* <br/>  ↑ efavirenz*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Monitor for elevation of liver enzymes and for adverse clinical experiences (e.g., dizziness, nausea, paresthesia) when Efavirenz is coadministered with ritonavir.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Protease inhibitor: <br/>  Saquinavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ saquinavir*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Appropriate doses of the combination of Efavirenz and saquinavir/ritonavir with respect to safety and efficacy have not been established.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> NNRTI: <br/>  Other NNRTIs<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↑ or ↓ efavirenz and/or NNRTI<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Combining two NNRTIs has not been shown to be beneficial. Efavirenz should not be coadministered with other NNRTIs.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> CCR5 co-receptor antagonist: <br/>  Maraviroc<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ maraviroc*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Refer to the full prescribing information for maraviroc for guidance on coadministration with efavirenz.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="italics">Hepatitis C antiviral agents </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Boceprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ boceprevir*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant administration of boceprevir with Efavirenz is not recommended because it may result in loss of therapeutic effect of boceprevir.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Elbasvir/Grazoprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ elbasvir<br/>  ↓ grazoprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">  Coadministration of Efavirenz with elbasvir/grazoprevir is contraindicated <content styleCode="italics">[see Contraindications (4)]</content>  because it may lead to loss of virologic response to elbasvir/grazoprevir<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Pibrentasvir/Glecaprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ pibrentasvir<br/>  ↓ glecaprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Coadministration of Efavirenz is not recommended because it may lead to reduced therapeutic effect of pibrentasvir/glecaprevir.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Simeprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ simprevir* <br/>  ↔ efavirenz*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant administration of simeprevir with efavirenz is not recommended because it may result in loss of therapeutic effect of simeprevir.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Velpatasvir/ Sofosbuvir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓velpatasvir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Coadministration of Efavirenz and sofosbuvir/velpatasvir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Velpatasvir/Sofosbuvir/Voxilaprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓velpatasvir<br/>  ↓voxilaprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Coadministration of Efavirenz and sofosbuvir/velpatasvir/voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/voxilaprevir<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left">
                                    <content styleCode="italics">Other agents </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Anticoagulant: <br/>  Warfarin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↑ or ↓ warfarin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Monitor INR and adjust warfarin dosage if necessary.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Anticonvulsants: Carbamazepine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ carbamazepine* <br/>  ↓ efavirenz*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> There are insufficient data to make a dose recommendation for efavirenz. Alternative anticonvulsant treatment should be used.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Phenytoin Phenobarbital<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ anticonvulsant <br/>  ↓ efavirenz<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Potential for reduction in anticonvulsant and/or efavirenz plasma levels; periodic monitoring of anticonvulsant plasma levels should be conducted.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Antidepressants: <br/>  Bupropion<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ bupropion*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Increases in bupropion dosage should be guided by clinical response. Bupropion dose should not exceed the maximum recommended dose.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Sertraline<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ sertraline*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Increases in sertraline dosage should be guided by clinical response.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Antifungals:<br/>  Voriconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ↓ voriconazole* <br/>  ↑ efavirenz*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left">  Efavirenz and voriconazole should not be coadministered at standard doses. When voriconazole is coadministered with efavirenz, voriconazole maintenance dose should be increased to 400 mg every 12 hours and efavirenz dose should be decreased to 300 mg once daily using the capsule formulation. Efavirenz tablets must not be broken <content styleCode="italics">[see Dosage and Administration (2.2) and Clinical Pharmacology (12.3, Tables 7 and 8)].</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Itraconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> ↓ itraconazole* <br/>  ↓hydroxyitraconazole*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="left"> Consider alternative antifungal treatment because no dose recommendation for itraconazole can be made.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Ketoconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ ketoconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider alternative antifungal treatment because no dose recommendation for ketoconazole can be made.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Posaconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ posaconazole*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Avoid concomitant use unless the benefit outweighs the risks.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Anthelmintic: <br/>  Praziquantel<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ praziquantel<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Coadministration with efavirenz is not recommended due to   significant decrease in plasma concentrations of praziquantel, with risk of treatment failure due to increased hepatic metabolism by efavirenz.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Anti-infective: <br/>  Clarithromycin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ clarithromycin* <br/>  ↑ 14-OH metabolite*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider alternatives to macrolide antibiotics because of the risk of QT interval prolongation.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Antimycobacterials: <br/>  Rifabutin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ rifabutin*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Increase daily dose of rifabutin by 50%. Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Rifampin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ efavirenz*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Increase Efavirenz to 800 mg once daily when coadministered with rifampin to patients weighing 50 kg or more.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Antimalarials: Artemether/ lumefantrine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ artemether* <br/>  ↓ dihydroartemisinin* <br/>  ↓ lumefantrine*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider alternatives to a artemether/ lumefantrine because of the risk of interval prolongation.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Atovaquone/ proguanil<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ atovaquone<br/>  ↓ proguanil<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant administration is not recommended.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Calcium channel blockers: Diltiazem<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ diltiazem* <br/>  ↓ desacetyl diltiazem* <br/>  ↓ N-monodesmethyl diltiazem*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem). No dose adjustment of efavirenz is necessary when administered with diltiazem.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Others (e.g., felodipine, nicardipine, nifedipine, verapamil)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ calcium channel blocker<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> When coadministered with Efavirenz, dosage adjustment of calcium channels blocker may be needed and should be guided by clinical response (refer to the full prescribing information for the calcium channel blocker).<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> HMG-CoA reductase inhibitors: <br/>  Atorvastatin <br/>  Pravastatin <br/>  Simvastatin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ atorvastatin* <br/>  ↓ pravastatin* <br/>  ↓ simvastatin*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased. Consult the full prescribing information for the HMG-CoA reductase inhibitor for guidance on individualizing the dose.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Hormonal contraceptives:<br/>  Oral <br/>  Ethinyl estradiol/ Norgestimate<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ active metabolites of norgestimate*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> A reliable method of barrier contraception should be used in addition to hormonal contraceptives.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Implant <br/>  Etonogestrel<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ etonogestrel<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> A reliable method of barrier contraception should be used in addition to hormonal contraceptives. Decreased exposure of etonogestrel may be expected. There have been postmarketing reports of contraceptive failure with etonogestrel in efavirenz-exposed patients.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Immunosuppressants: <br/>  Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ immunosuppressant<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Dose adjustments of the immunosuppressant may be required. Close monitoring of immunosuppressant concentrations for at least 2 weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with efavirenz.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Narcotic analgesic: <br/>  Methadone<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ↓ methadone*<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Monitor for signs of methadone withdrawal and increase methadone dose if required to alleviate withdrawal symptoms.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <sup>*</sup> The interaction between Efavirenz and the drug was evaluated in a clinical study. All other drug interactions shown are predicted. This table is not all-inclusive<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID87">
                     <id root="5ed1da9d-7fe3-4c92-926b-90b319c1dfe6"/>
                     <title>7.5 Drugs Without Clinically Significant Interactions with Efavirenz</title>
                     <text>
                        <paragraph ID="ID88">No dosage adjustment is recommended when Efavirenz is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lorazepam, nelfinavir, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine), paroxetine, and raltegravir.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID89">
                     <id root="c34847c1-31d1-4983-840c-d867ca200fe6"/>
                     <title>7.6 Cannabinoid Test Interaction</title>
                     <text>
                        <paragraph ID="ID90">Efavirenz does not bind to cannabinoid receptors. False-positive urine cannabinoid test results have been reported with some screening assays in uninfected and HIV-infected subjects receiving efavirenz. Confirmation of positive screening tests for cannabinoids by a more specific method is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID91">
               <id root="9434b8da-49fb-400b-9176-2063038b8654"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20231213"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID93" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Lactation: </content>  Breastfeeding not recommended. (8.2)</item>
                           <item>
                              <content styleCode="italics">Females and Males of Reproductive Potential:</content> Pregnancy testing and contraception are recommended. (8.3)</item>
                           <item>
                              <content styleCode="italics">Hepatic impairment:</content> Efavirenz is not recommended for patients with moderate or severe hepatic impairment.  Use caution in patients with mild hepatic impairment. (8.6)</item>
                           <item>
                              <content styleCode="italics">Pediatric patients:</content> The incidence of rash was higher than in adults. (5.8, 6.2, 8.4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID94">
                     <id root="03a0f9b0-0795-47b1-9e1e-7fb019595809"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID95">
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Efavirenz during pregnancy. Physicians are encouraged to register patients by calling the Antiretroviral Pregnancy Registry at 1-800-258-4263. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are retrospective case reports of neural tube defects in infants whose mothers were exposed to efavirenz containing regimens in the first trimester of pregnancy. Prospective pregnancy data from the Antiretroviral Pregnancy Registry are not sufficient to adequately assess this risk. Available data from the Antiretroviral Pregnancy Registry show no difference in the risk of overall major birth defects compared to the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). Although a causal relationship has not been established between exposure to efavirenz in the first trimester and neural tube defects, similar malformations have been observed in studies conducted in monkeys at doses similar to the human dose. In addition, fetal and embryonic toxicities occurred in rats, at a dose ten times less than the human exposure at recommended clinical dose. Because of the potential risk of neural tube defects, efavirenz should not be used in the first trimester of pregnancy. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>There are retrospective postmarketing reports of findings consistent with neural tube defects, including meningomyelocele, all in infants of mothers exposed to efavirenz-containing regimens in the first trimester.</paragraph>
                        <paragraph>Based on prospective reports from the Antiretroviral Pregnancy Registry (APR) of approximately 1000 live births following exposure to efavirenz containing regimens (including over 800 live births exposed in the first trimester), there was no difference between efavirenz and overall birth defects compared with the background birth defect rate of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program. As of the interim APR report issued December 2014, the prevalence of birth defects following first-trimester exposure was 2.3% (95% CI: 1.4%-3.6%). One of these prospectively reported defects with first-trimester exposure was a neural tube defect. A single case of anophthalmia with first-trimester exposure to efavirenz has also been prospectively reported. This case also included severe oblique facial clefts and amniotic banding, which have a known association with anophthalmia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Effects of efavirenz on embryo-fetal development have been studied in three nonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, efavirenz 60 mg/kg/day was administered to pregnant females throughout pregnancy (gestation days 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the exposure in humans at the recommended clinical dose (600 mg/day), with fetal umbilical venous drug concentrations approximately 0.7 times the maternal values. Three of 20 fetuses/infants had one or more malformations; there were no malformed fetuses or infants from placebo-treated mothers. The malformations that occurred in these three monkey fetuses included anencephaly and unilateral anophthalmia in one fetus, microphthalmia in a second, and cleft palate in the third. There was no NOAEL (no observable adverse effect level) established for this study because only one dosage was evaluated. In rats, efavirenz was administered either during organogenesis (gestation days 7 to 18) or from gestation day 7 through lactation day 21 at 50, 100, or 200 mg/kg/day. Administration of 200 mg/kg/day in rats was associated with increase in the incidence of early resorptions; and doses 100 mg/kg/day and greater were associated with early neonatal mortality. The AUC at the NOAEL (50 mg/kg/day) in this rat study was 0.1 times that in humans at the recommended clinical dose. Drug concentrations in the milk on lactation day 10 were approximately 8 times higher than those in maternal plasma. In pregnant rabbits, efavirenz was neither embryo lethal nor teratogenic when administered at doses of 25, 50, and 75 mg/kg/day over the period of organogenesis (gestation days 6 through 18). The AUC at the NOAEL (75 mg/kg/day) in rabbits was 0.4 times that in humans at the recommended clinical dose.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID96">
                     <id root="b116f90b-7733-4c95-817d-640da5f025e7"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID97">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV. Because of the potential for HIV transmission in breastfed infants, advise women not to breastfeed.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID98">
                     <id root="eb194c63-3038-4467-9a98-cdc740b68caf"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph ID="ID99">Because of potential teratogenic effects, pregnancy should be avoided in women receiving Efavirenz <content styleCode="italics">[See Use in Specific Populations (8.1)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Females of reproductive potential should undergo pregnancy testing before initiation of Efavirenz.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>Females of reproductive potential should use effective contraception during treatment with Efavirenz and for 12 weeks after discontinuing Efavirenz due to the long half-life of efavirenz. Barrier contraception should always be used in combination with other methods of contraception. Hormonal methods that contain progesterone may have decreased effectiveness <content styleCode="italics">[see Drug Interactions (7.1)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID100">
                     <id root="28e26a72-9048-4125-9517-535d31d607c5"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID101">The safety, pharmacokinetic profile, and virologic and immunologic responses of Efavirenz were evaluated in antiretroviral-naive and -experienced HIV-1 infected pediatric patients 3 months to 21 years of age in three open-label clinical trials <content styleCode="italics">[see Adverse Reactions (6.2), Clinical Pharmacology (12.3), and Clinical Studies (14.2)].</content> The type and frequency of adverse reactions in these trials were generally similar to those of adult patients with the exception of a higher frequency of rash, including a higher frequency of Grade 3 or 4 rash, in pediatric patients compared to adults <content styleCode="italics">[see Warnings and Precautions (5.8) and Adverse Reactions (6.2)].</content>
                        </paragraph>
                        <paragraph>Use of Efavirenz in patients younger than 3 months of age OR less than 3.5 kg body weight is not recommended because the safety, pharmacokinetics, and antiviral activity of Efavirenz have not been evaluated in this age group and there is a risk of developing HIV resistance if Efavirenz is underdosed. See<content styleCode="italics"> Dosage and Administration (2.2)</content> for dosing recommendations for pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID102">
                     <id root="4e78a24f-21e5-40dc-86b8-3dd240597d3e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID103">Clinical studies of Efavirenz did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other therapy.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID104">
                     <id root="d07867e1-cba1-4666-be81-f4747f9d1335"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID105">Efavirenz is not recommended for patients with moderate or severe hepatic impairment because there are insufficient data to determine whether dose adjustment is necessary. Patients with mild hepatic impairment may be treated with efavirenz without any adjustment in dose. Because of the extensive cytochrome P450-mediated metabolism of efavirenz and limited clinical experience in patients with hepatic impairment, caution should be exercised in administering Efavirenz to these patients <content styleCode="italics">[see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID106">
               <id root="49ec97e9-47e5-47d3-9949-e3d21efedf38"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID107">Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.</paragraph>
                  <paragraph>Treatment of overdose with Efavirenz should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Administration of activated charcoal may be used to aid removal of unabsorbed drug. There is no specific antidote for overdose with Efavirenz. Since efavirenz is highly protein bound, dialysis is unlikely to significantly remove the drug from blood.</paragraph>
               </text>
               <effectiveTime value="20200908"/>
            </section>
         </component>
         <component>
            <section ID="ID108">
               <id root="a60b6ead-09ad-4b79-9251-78efc3511695"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID109">Efavirenz tablet USP is an HIV-1 specific, non-nucleoside, reverse transcriptase inhibitor (NNRTI). Efavirenz is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. Its empirical formula is C<sub>14</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>2</sub> and its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID172">Efavirenz is a white to off-white crystalline powder with a molecular mass of 315.68. It is practically insoluble in water (&lt;10 microgram/mL).</paragraph>
                  <paragraph>Efavirenz tablet USP is available as capsule shaped film-coated tablets imprinted with "EFZ" on one side and plain on other side for oral administration containing 600 mg of efavirenz and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The film coating contains Instacoat Universal/Opacode black ink. Instacoat Universal contains HPMC 2910/Hypromellose, titanium dioxide, polyethylene glycol, red iron oxide, black iron oxide and yellow iron oxide. Opacode black ink contains propylene glycol, shellac glaze and ferrosoferric oxide.</paragraph>
                  <paragraph>FDA approved dissolution method differs from that of the USP.</paragraph>
               </text>
               <effectiveTime value="20210216"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="b02a7bf3-5dfa-4afe-8093-a2c0250d8798-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID110">
               <id root="79e8e6c7-2aed-44b4-b2a7-f5814b003ea9"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20231213"/>
               <component>
                  <section ID="ID111">
                     <id root="3cb806fb-cace-4f6e-9e28-890a0d5c42d5"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID112">Efavirenz is an antiviral drug <content styleCode="italics">[see Microbiology (12.4)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID113">
                     <id root="125679f1-f4da-497b-b86e-0982fd54ad83"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID114">Cardiac Electrophysiology </paragraph>
                        <paragraph>The effect of Efavirenz on the QTc interval was evaluated in an open-label, positive and placebo controlled, fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C<sub>max </sub>of efavirenz in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean C<sub>max</sub> observed in subjects with CYP2B6 *1/*1 genotype. A positive relationship between efavirenz concentration and QTc prolongation was observed. Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days <content styleCode="italics">[see Warnings and Precautions (5.2)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID115">
                     <id root="b401de58-a82a-43a0-b78b-cef106efa343"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID116">Absorption</paragraph>
                        <paragraph>Peak efavirenz plasma concentrations of 1.6 - 9.1 μM were attained by 5 hours following single oral doses of 100 mg to 1600 mg administered to uninfected volunteers. Dose-related increases in C<sub>max</sub> and AUC were seen for doses up to 1600 mg; the increases were less than proportional suggesting diminished absorption at higher doses.</paragraph>
                        <paragraph>In HIV-1-infected patients at steady state, mean C<sub>max</sub>, mean C<sub>min</sub>, and mean AUC were dose proportional following 200 mg, 400 mg, and 600 mg daily doses. Time-to-peak plasma concentrations were approximately 3-5 hours and steady-state plasma concentrations were reached in 6-10 days. In 35 patients receiving Efavirenz 600 mg once daily, steady-state C<sub>max</sub> was 12.9 ± 3.7 μM (mean ± SD), steady-state C<sub>min</sub> was 5.6 ± 3.2 μM, and AUC was 184 ±73 μM•h.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food on Oral Absorption:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Tablets: </content>Administration of a single 600 mg efavirenz tablet with a high-fat/high-caloric meal (approximately 1000 kcal, 500-600 kcal from fat) was associated with a 28% increase in mean AUC<sub>∞</sub> of efavirenz and a 79% increase in mean C<sub>max</sub> of efavirenz relative to the exposures achieved under fasted conditions <content styleCode="italics">[see Dosage and Administration (2) and Patient Counseling Information (17)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Capsules</content>: Administration of a single 600 mg dose of efavirenz capsules with a high-fat/high-caloric meal (894 kcal, 54 g fat, 54% calories from fat) or a reduced-fat/normal-caloric meal (440 kcal, 2 g fat, 4% calories from fat) was associated with a mean increase of 22% and 17% in efavirenz AUC<sub>∞ </sub>and a mean increase of 39% and 51% in efavirenz C<sub>max</sub>, respectively, relative to the exposures achieved when given under fasted conditions <content styleCode="italics">[see Dosage and Administration (2) and Patient Counseling Information (17)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bioavailability of capsule contents mixed with food vehicles:</content>
                        </paragraph>
                        <paragraph>In healthy adult subjects, the efavirenz AUC when administered as the contents of three 200 mg capsules mixed with 2 teaspoons of certain food vehicles (applesauce, grape jelly or yogurt, or infant formula) met bioequivalency criteria for the AUC of the intact capsule formulation administered under fasted conditions.</paragraph>
                        <paragraph>Distribution</paragraph>
                        <paragraph>Efavirenz is highly bound (approximately 99.5-99.75%) to human plasma proteins, predominantly albumin. In HIV-1 infected patients (n=9) who received Efavirenz 200 to 600 mg once daily for at least one month, cerebrospinal fluid concentrations ranged from 0.26 to 1.19% (mean 0.69%) of the corresponding plasma concentration. This proportion is approximately 3-fold higher than the non-protein-bound (free) fraction of efavirenz in plasma.</paragraph>
                        <paragraph>Metabolism</paragraph>
                        <paragraph>Studies in humans and <content styleCode="italics">in vitro </content>studies using human liver microsomes have demonstrated that efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1. The <content styleCode="italics">in vitro</content> studies suggest that CYP3A and CYP2B6 are the major isozymes responsible for efavirenz metabolism. </paragraph>
                        <paragraph>Efavirenz has been shown to induce CYP enzymes, resulting in the induction of its own metabolism. Multiple doses of 200 - 400 mg per day for 10 days resulted in a lower than predicted extent of accumulation (22 - 42% lower) and a shorter terminal half-life of 40 - 55 hours (single dose half-life 52 - 76 hours). </paragraph>
                        <paragraph>Elimination</paragraph>
                        <paragraph>Efavirenz has a terminal half-life of 52 - 76 hours after single doses and 40 - 55 hours after multiple doses. A one-month mass balance/excretion study was conducted using 400 mg per day with a <sup>14</sup>C-labeled dose administered on Day 8. Approximately 14-34% of the radiolabel was recovered in the urine and 16 - 61% was recovered in the feces. Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites. Efavirenz accounted for the majority of the total radioactivity measured in feces.</paragraph>
                        <paragraph>Special Populations</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric:</content> The pharmacokinetic parameters for efavirenz at steady state in pediatric patients were predicted by a population pharmacokinetic model and are summarized in Table 6 by weight ranges that correspond to the recommended doses.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 6: Predicted Steady-State Pharmacokinetics of Recommended Doses of Efavirenz (Capsules/Capsule Sprinkles) in HIV-Infected Pediatric Patients</content>
                        </paragraph>
                        <table ID="ID117" width="100%" styleCode="Noautorules">
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Body weight</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Dose</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Mean AUC <sub>(0-24)</sub> µ M.h</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Mean C<sub>max</sub>      µg/mL</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">  Mean C<sub>min </sub>     µg/mL</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 3.5-5 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 100 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 220.52<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5.81<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.43<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 5-7.5 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 150 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 262.62<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.07<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.71<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 7.5-10 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 200 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 284.28<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.75<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.87<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 10-15 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 200 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 238.14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.54<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.32<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 15-20 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 250 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 233.98<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.47<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 20-25 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 300 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 257.56<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.04<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.55<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 25-32.5 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 350 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 262.37<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.68<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 32.5-40 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 259.79<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.96<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.69<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> &gt;40 kg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 600 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 254.78<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.57<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.82<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID118">
                           <content styleCode="italics">Gender and race: </content>The pharmacokinetics of efavirenz in patients appear to be similar between men and women and among the racial groups studied.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal impairment: </content>The pharmacokinetics of efavirenz have not been studied in patients with renal insufficiency; however, less than 1% of efavirenz is excreted unchanged in the urine, so the impact of renal impairment on efavirenz elimination should be minimal.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic impairment:</content> A multiple-dose study showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh Class A) compared with controls. There were insufficient data to determine whether moderate or severe hepatic impairment (Child-Pugh Class B or C) affects efavirenz pharmacokinetics.</paragraph>
                        <paragraph>Drug Interaction Studies</paragraph>
                        <paragraph>Efavirenz has been shown <content styleCode="italics">in vivo</content> to cause hepatic enzyme induction, thus increasing the biotransformation of some drugs metabolized by CYP3A and CYP2B6. <content styleCode="italics">In vitro</content> studies have shown that efavirenz inhibited CYP isozymes 2C9 and 2C19 with K<sub>i</sub> values (8.5-17 μM) in the range of observed efavirenz plasma concentrations. In <content styleCode="italics">in vitro</content> studies, efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 (K<sub>i</sub> values 82-160 μM) only at concentrations well above those achieved clinically. Coadministration of efavirenz with drugs primarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in altered plasma concentrations of the coadministered drug. Drugs which induce CYP3A and CYP2B6 activity would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.</paragraph>
                        <paragraph>Drug interaction studies were performed with efavirenz and other drugs likely to be coadministered or drugs commonly used as probes for pharmacokinetic interaction. The effects of coadministration of efavirenz on the C<sub>max</sub>, AUC, and C<sub>min</sub> are summarized in Table 7 (effect of efavirenz on other drugs) and Table 8 (effect of other drugs on efavirenz). For information regarding clinical recommendations see <content styleCode="italics">Drug Interactions (7.1)</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 7: Effect of Efavirenz on Coadministered Drug Plasma C<sub>max</sub>, AUC, and C<sub>min</sub>
                           </content>
                        </paragraph>
                        <table ID="ID119" width="100%" styleCode="Noautorules">
                           <col width="19%"/>
                           <col width="16%"/>
                           <col width="13%"/>
                           <col width="10%"/>
                           <col width="12%"/>
                           <col width="15%"/>
                           <col width="11%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">↑ Indicates increase ↓ Indicates decrease ↔ Indicates no change or a mean increase or decrease of &lt;10%.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> Compared with atazanavir 400 mg qd alone.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Comparator dose of indinavir was 800 mg q8h x 10 days.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> Parallel-group design; n for efavirenz + lopinavir/ritonavir, n for lopinavir/ritonavir alone.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>d </sup>Values are for lopinavir; the pharmacokinetics of ritonavir in this study were unaffected by concurrent efavirenz.  </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>e</sup> 95% CI.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>f</sup> Soft Gelatin Capsule.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>g</sup> Tenofovir disoproxil fumarate.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>h </sup>90% CI not available.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>i</sup> Relative to steady-state administration of voriconazole (400 mg for 1 day, then 200 mg po q12h for 2 days).</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>j</sup> Not available because of insufficient data.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">NA= not available.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> Coadministered Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> Dose</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> Efavirenz Dose</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> Number</content>
                                    <br/>
                                    <content styleCode="bold"> of</content>
                                    <br/>
                                    <content styleCode="bold"> Subjects</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" align="center">
                                    <content styleCode="bold"> Coadministered Drug</content>
                                    <br/>
                                    <content styleCode="bold"> (mean % change)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (90% CI)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> AUC</content>
                                    <br/>
                                    <content styleCode="bold"> (90% CI)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> C<sub>min</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (90% CI)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Atazanavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd with a light meal d 1-20<br/> 400 mg qd d 1-6, then 300 mg qd<br/> d 7-20 with<br/> ritonavir 100 mg<br/> qd and a light<br/> meal<br/> 300 mg qd/ritonavir 100mg qd d 1-10 (pm), then 400 mg qd/ritonavir 100 mg qd d 11-24 (pm) (simultaneous with efavirenz)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd with a light meal<br/> d 7-20<br/> 600 mg qd 2 h after<br/> atazanavir and ritonavir<br/> d 7-20<br/> 600 mg qd with a light snack d 11-24 (pm)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 27<br/> 13<br/> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 59%<br/> (49-67%)<br/> ↑ 14%<sup>a</sup>
                                    <br/> (↓ 17-↑ 58%)<br/> ↑ 17%<br/> (8-27%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 74%<br/> (68-78%)<br/> ↑ 39%<sup>a</sup>
                                    <br/> (2-88%)<br/> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 93%<br/> (90-95%)<br/> ↑ 48%<sup>a</sup>
                                    <br/> (24-76%)<br/> ↓ 42%<br/> (31-51%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Indinavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 1000 mg q8h x<br/> 10 days<br/> After morning dose<br/> After afternoon dose<br/> After evening dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 20<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<sup>b</sup>
                                    <br/>
                                    <br/>
                                    <br/> ↔<sup>b</sup>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/> ↓ 29%<sup>b</sup>
                                    <br/> (11-43%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 33%<sup>b</sup>
                                    <br/> (26-39%)<br/> ↓ 37%<sup>b</sup>
                                    <br/> (26-46%)<br/> ↓ 46%<sup>b</sup>
                                    <br/> (37-54%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 39%<sup>b</sup>
                                    <br/> (24-51%)<br/> ↓ 52%<sup>b</sup>
                                    <br/> (47-57%)<br/> ↓ 57%<sup>b</sup>
                                    <br/> (50-63%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Lopinavir/ ritonavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400/100 mg capsule q12h x 9 days<br/> 500/125 mg tablet q12h x 10 days with efavirenz compared to 400/100 mg q 12h alone<br/> 600/150 mg tablet  q12h x 10 days with  efavirenz compared to 400/100 mg q12h alone<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 9 days<br/> 600 mg qd x 9 days<br/> 600 mg qd x<br/> 9 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11,7<sup>c</sup>
                                    <br/>
                                    <br/>
                                    <br/>
                                    <br/> 19<br/> 23<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<sup>d</sup>
                                    <br/> ↑ 12%<sup>d</sup> (2-23%) <br/> ↑ 36%<sup>d</sup>
                                    <br/> (28-44%)<br/>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 19%<sup>d</sup>
                                    <br/> (↓ 36-↑ 3%)<br/> ↔<sup>d</sup>
                                    <br/> ↑ 36%<sup>d</sup>
                                    <br/> (28-44%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 39%<sup>d</sup>
                                    <br/> (3-62%)<br/> ↓ 10%<sup>d</sup>
                                    <br/> (↓ 22-↑ 4%)<br/> ↑ 32%<sup>d</sup>
                                    <br/> (21-44%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Nelfinavir<br/> Metabolite<br/> AG-1402<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 750 mg q8h x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 21%<br/> (10-33%)<br/> ↓ 40%<br/> (30-48%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 20%<br/> (8-34%)<br/> ↓ 37%<br/> (25-48%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/> ↓ 43%<br/> (21-59%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Ritonavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 500 mg q12h x<br/> 8 days<br/> After AM dose<br/> After PM dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 24%<br/> (12-38%)<br/> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 18%<br/> (6-33%)<br/> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 42%<br/> (9-86%)<sup>e</sup>
                                    <br/> ↑ 24%<br/> (3-50%)<sup>e</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Saquinavir<br/> SGC<sup>f</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 1200 mg q8h x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 50%<br/> (28-66%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 62%<br/> (45-74%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 56%<br/> (16-77%)<sup>e</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Lamivudine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 150 mg q12h x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 265%<br/> (37-873%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Tenofovir<sup>g</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 300 mg qd<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 29<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Zidovudine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 300 mg q12h x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 225%<br/> (43-640%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Maraviroc<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 100 mg bid<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓51%<br/> (37-62%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓45%<br/> (38-51%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓45%<br/> (28-57%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Raltegravir               <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg single dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd                  <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="left">        ↓ 36%<br/>       (2-59%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 36%<br/> (20-48%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓21%<br/> (↓51-↑28%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Boceprevir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 800 mg tid x 6 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x 16 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 8%<br/> (↓22-↑8%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓19%<br/> (11-25%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 44%<br/> (26-58%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Simeprevir <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 150 mg qd x 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 23<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 51%<br/> (↓46-↑56%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 71%<br/> (↓67-↑74%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 91%<br/> (↓88-↑92%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Azithromycin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg single dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 22%<br/> (4-42%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Clarithromycin<br/> 14-OH metabolite<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 500 mg q12h x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 26%<br/> (15-35%)<br/> ↑ 49%<br/> (32-69%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 39%<br/> (30-46%)<br/> ↑ 34%<br/> (18-53%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 53%<br/> (42-63%)<br/> ↑ 26%<br/> (9-45%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Fluconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 200 mg x 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Itraconazole<br/> Hydroxy-itraconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 200 mg q12h x<br/> 28 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 18<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 37%<br/> (20-51%)<br/> ↓ 35%<br/> (12-52%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 39%<br/> (21-53%)<br/> ↓ 37%<br/> (14-55%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 44%<br/> (27-58%)<br/> ↓ 43%<br/> (18-60%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Posaconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg (oral suspension) bid x 10 and 20 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x 10 and 20 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓45%<br/> (34-53%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓50%<br/> (40-57%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Rifabutin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 300 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 32%<br/> (15-46%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 38%<br/> (28-47%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 45%<br/> (31-56%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Voriconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg po q12h x 1 day, then 200 mg<br/> po q12h x 8 days<br/> 300 mg po q12h<br/> days 2-7<br/> 400 mg po q12h<br/> days 2-7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 9 days<br/> 300 mg qd x<br/> 7 days<br/> 300 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/> NA<br/> NA<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 61%<sup>h</sup>
                                    <br/> ↓ 36%<sup>i</sup>
                                    <br/> (21-49%)<br/> ↑ 23%<sup>i</sup>
                                    <br/> (↓ 1-↑ 53%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 77%<sup>h</sup>
                                    <br/> ↓ 55%<sup>i</sup>
                                    <br/> (45-62%)<br/> ↓ 7%<sup>i</sup>
                                    <br/> (↓ 23-↑ 13%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/> NA<br/> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Artemether/<br/> Lumefantrine<br/> Artemether<br/> dihydroartemisinin<br/> Lumefantrine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> Artemether 20 mg/lumfantrine 120 mg tablets (64-tablet doses over 3 days)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 26 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 21%<br/> ↓ 38%<br/> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 51%<br/> ↓ 46%<br/> ↓ 21%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>      NA<br/>      <br/>      NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Atorvastatin<br/> Total active (including metabolites)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10 mg qd x<br/> 4 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 15 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 14%<br/> (1-26%)<br/> ↓ 15%<br/> (2-26%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 43%<br/> (34-50%)<br/> ↓ 32%<br/> (21-41%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 69%<br/> (49-81%)<br/> ↓ 48%<br/> (23-64%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Pravastatin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 40 mg qd x<br/> 4 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 15 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 13<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 32%<br/> (↓59-↑ 12%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 44%<br/> (26-57%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 19%<br/> (0-35%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Simvastatin<br/> Total active (including metabolites)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 40 mg qd x<br/> 4 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 15 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 72%<br/> (63-79%)<br/> ↓ 68%<br/> (55-78%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 68%<br/> (62-73%)<br/> ↓ 60%<br/> (52-68%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 45%<br/> (20-62%)<br/> NA<sup>j</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Carbamazepine<br/> Epoxide metabolite<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 200 mg qd x 3 days,<br/> 200 mg bid x<br/> 3 days, then<br/> 400 mg qd x<br/> 29 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 20%<br/> (15-24%)<br/> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 27%<br/> (20-33%)<br/> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 35%<br/> (24-44%)<br/> ↓ 13%<br/> (↓30-↑ 7%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Cetirizine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10 mg single<br/> dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 24%<br/> (18-30%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Diltiazem<br/> Desacetyl diltiazem<br/> N-monodes-methyl<br/> diltiazem<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 240 mg x<br/> 21 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 13<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 60%<br/> (50-68%)<br/> ↓ 64%<br/> (57-69%)<br/> ↓ 28%<br/> (7-44%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 69%<br/> (55-79%)<br/> ↓ 75%<br/> (59-84%)<br/> ↓ 37%<br/> (17-52%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 63%<br/> (44-75%)<br/> ↓ 62%<br/> (44-75%)<br/> ↓ 37%<br/> (17-52%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Ethinyl estradiol/     Norgestimate<br/> Ethinyl estradiol<br/> Norelgestromin<br/> Levonorgestrel<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 0.035 mg/  0.25 mg x 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 21<br/> 21<br/> 6<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/> ↓ 46%  (39-52%)<br/> ↓ 80%   (77-83%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/> ↓ 64%  (62-67%)<br/> ↓ 83%  (79-87%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/> ↓ 82%  (79-85%)<br/> ↓ 86%  (80-90%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Lorazepam<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 2 mg single dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 16%<br/> (2-32%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Methadone<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> Stable maintenance<br/> 35-100 mg daily<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14-21 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 45%<br/> (25-59%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 52%<br/> (33-66%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Bupropion<br/> Hydroxy – <br/> bupropion<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 150 mg single dose<br/> (sustained-release)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 13<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 34%<br/> (21-47%)<br/> ↑ 50%<br/> (20-80%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 55%<br/> (48-62%)<br/> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Paroxetine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 20 mg qd x 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 16<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Sertraline<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 50 mg qd x 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 13<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 29%<br/> (15-40%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 39%<br/> (27-50%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 46%<br/> (31-58%)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID120">
                           <content styleCode="bold">Table 8: Effect of Coadministered Drug on Efavirenz Plasma C<sub>max</sub>, AUC, and C<sub>min</sub>
                           </content>
                        </paragraph>
                        <table ID="ID121" width="100%" styleCode="Noautorules">
                           <col width="17%"/>
                           <col width="16%"/>
                           <col width="15%"/>
                           <col width="10%"/>
                           <col width="12%"/>
                           <col width="14%"/>
                           <col width="13%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">↑ Indicates increase     ↓ Indicates decrease    ↔ Indicates no change or a mean increase or decrease of &lt;10%.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> Parallel-group design; n for efavirenz + lopinavir/ritonavir, n for efavirenz alone.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> 95% CI.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> Soft Gelatin Capsule.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>d</sup> Tenofovir disoproxil fumarate. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>e</sup> 90% CI not available.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>f</sup> Relative to steady-state administration of efavirenz (600 mg once daily for 9 days).</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">  NA = not available.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top" align="left">
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Botrule" align="center">
                                    <content styleCode="bold"> Efavirenz </content>
                                    <br/>
                                    <content styleCode="bold"> (mean % change)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" align="left">
                                    <br/>
                                    <content styleCode="bold"> Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug</content>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center">
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> Dose</content>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center">
                                    <br/>
                                    <content styleCode="bold"> Efavirenz</content>
                                    <br/>
                                    <content styleCode="bold"> Dose</content>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center">
                                    <content styleCode="bold"> Number </content>
                                    <br/>
                                    <content styleCode="bold"> of</content>
                                    <br/>
                                    <content styleCode="bold"> Subjects</content>
                                    <br/>
                                 </td>
                                 <td valign="top" align="center">
                                    <br/>
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (90% CI)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule" align="center">
                                    <br/>
                                    <content styleCode="bold"> AUC</content>
                                    <br/>
                                    <content styleCode="bold"> (90% CI)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule" align="center">
                                    <br/>
                                    <content styleCode="bold"> C<sub>min</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (90% CI)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Indinavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 800 mg q8h x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 200 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Lopinavir/ ritonavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400/100 mg<br/> q12h x 9 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 9 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11,12<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 16%<br/> (↓ 38-↑ 15%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 16%<br/> (↓ 42-↑ 20%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Nelfinavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 750 mg q8h x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 12%<br/> (↓ 32-↑ 13%)<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 12%<br/> (↓ 35-↑ 18%)<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 21%<br/> (↓ 53-↑ 33%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Ritonavir<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 500 mg q12h x 8 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 14%<br/> (4-26%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 21%<br/> (10-34%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 25%<br/> (7-46%)<sup>b</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Saquinavir<br/> SGC<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 1200 mg q8h x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 13<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 13%<br/> (5-20%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 12%<br/> (4-19%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 14%<br/> (2-24%)<sup> b</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Tenofovir<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 300 mg qd<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 30<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Boceprevir                          <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 800 mg tid x 6           days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x 16days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑11%<br/> (2-20%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑20%<br/> (15-26%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Simeprevir <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 150 mg qd x 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x 14days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 23<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓10%<br/> (5-15%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓13%<br/> (7-19%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Azithromycin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg single<br/> dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Clarithromycin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 500 mg q12h<br/> x 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 11%<br/> (3-19%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Fluconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 200 mg x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 16%<br/> (6-26%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 22%<br/> (5-41%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Itraconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 200 mg q12h x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 28 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 16<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Rifabutin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 300 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 12%<br/> (↓ 24-↑ 1%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Rifampin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 20%<br/> (11-28%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 26%<br/> (15-36%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 32%<br/> (15-46%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Voriconazole<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg po<br/> q12h x 1 day,<br/> then 200 mg<br/> po q12h x<br/> 8 days<br/> 300 mg po<br/> q12h days 2-7<br/> 400 mg po<br/> q12h days 2-7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg qd x<br/> 9 days<br/> 300 mg qd x<br/> 7 days<br/> 300 mg qd x<br/> 7 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/> NA<br/> NA<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 38%<sup>e</sup>
                                    <br/> ↓ 14%<sup>f</sup>
                                    <br/> (7-21%)<br/> ↔<sup>f</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 44%<sup>e</sup>
                                    <br/> ↔<sup>f</sup>
                                    <br/> ↑ 17%<sup>f</sup>
                                    <br/> (6-29%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/> NA<br/> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Artemether/ Lumefantrine <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> Artemether 20 mg/ lumefantrine 120 mg tablets (6 4-tablet doses over 3 days)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x 26 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 17%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Atorvastatin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10 mg qd x<br/> 4 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 15 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Pravastatin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 40 mg qd x<br/> 4 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 15 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Simvastatin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 40 mg qd x<br/> 4 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 15 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 12%<br/> (↓ 28-↑ 8%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 12%<br/> (↓ 25-↑ 3%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Aluminium hydroxide 400 mg, magnesium hydroxide 400 mg, plus simethicone 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 30 mL single<br/> dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg single dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 17<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Carbamazepine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 200 mg qd x 3<br/> days, 200 mg<br/> bid x 3 days,<br/> then 400 mg<br/> qd x 15 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 35 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 14<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 21%<br/> (15-26%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 36%<br/> (32-40%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↓ 47%<br/> (41-53%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Cetirizine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 10 mg single<br/> dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 10 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Diltiazem<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 240 mg x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 28 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 16%<br/> (6-26%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 11%<br/> (5-18%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 13%<br/> (1-26%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Famotidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 40 mg single<br/> dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 400 mg single dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 17<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Paroxetine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 20 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 12<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="left"> Sertraline<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 50 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 600 mg qd x<br/> 14 days<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 13<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↑ 11%<br/> (6-16%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> ↔<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID122">
                     <id root="7e8049ef-6909-416f-94b4-02bea1cafcac"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph ID="ID123">Mechanism of Action</paragraph>
                        <paragraph>Efavirenz is an NNRTI of HIV-1. Efavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. HIV-2 reverse transcriptase and human cellular DNA polymerases α, β, γ, and δ are not inhibited by efavirenz. </paragraph>
                        <paragraph>Antiviral Activity in Cell Culture</paragraph>
                        <paragraph>The concentration of efavirenz inhibiting replication of wild-type laboratory adapted strains and clinical isolates in cell culture by 90-95% (EC<sub>90-95</sub>) ranged from 1.7 to 25 nM in lymphoblastoid cell lines, peripheral blood mononuclear cells (PBMCs), and macrophage/monocyte cultures. Efavirenz demonstrated antiviral activity against clade B and most non-clade B isolates (subtypes A, AE, AG, C, D, F, G, J, N), but had reduced antiviral activity against group O viruses. Efavirenz demonstrated additive antiviral activity without cytotoxicity against HIV-1 in cell culture when combined with the NNRTIs delavirdine and nevirapine, NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, zidovudine), PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir), and the fusion inhibitor enfuvirtide. Efavirenz demonstrated additive to antagonistic antiviral activity in cell culture with atazanavir. Efavirenz was not antagonistic with adefovir, used for the treatment of hepatitis B virus infection, or ribavirin, used in combination with interferon for the treatment of hepatitis C virus infection. </paragraph>
                        <paragraph>Resistance</paragraph>
                        <paragraph>
                           <content styleCode="italics">In cell culture</content>
                        </paragraph>
                        <paragraph>In cell culture, HIV-1 isolates with reduced susceptibility to efavirenz (&gt;380-fold increase in EC<sub>90</sub> value) emerged rapidly in the presence of drug. Genotypic characterization of these viruses identified single amino acid substitutions L100I or V179D, double substitutions L100I/V108I, and triple substitutions L100I/V179D/Y181C in reverse transcriptase.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical studies</content>
                        </paragraph>
                        <paragraph>Clinical isolates with reduced susceptibility in cell culture to efavirenz have been obtained. One or more substitutions at amino acid positions 98, 100, 101, 103, 106, 108, 188, 190, 225, and 227 in reverse transcriptase were observed in patients failing treatment with efavirenz in combination with indinavir, or with zidovudine plus lamivudine. The K103N substitution was the most frequently observed. Long-term resistance surveillance (average 52 weeks, range 4-106 weeks) analyzed 28 matching baseline and virologic failure isolates. Sixty-one percent (17/28) of these failure isolates had decreased efavirenz susceptibility in cell culture with a median 88-fold change in efavirenz susceptibility (EC<sub>50</sub> value) from reference. The most frequent NNRTI substitution to develop in these patient isolates was K103N (54%). Other NNRTI substitutions that developed included L100I (7%), K101E/Q/R (14%), V108I (11%), G190S/T/A (7%), P225H (18%), and M230I/L (11%).</paragraph>
                        <paragraph>Cross-Resistance</paragraph>
                        <paragraph>Cross-resistance among NNRTIs has been observed. Clinical isolates previously characterized as efavirenz-resistant were also phenotypically resistant in cell culture to delavirdine and nevirapine compared to baseline. Delavirdine- and/or nevirapine-resistant clinical viral isolates with NNRTI resistance-associated substitutions (A98G, L100I, K101E/P, K103N/S, V106A, Y181X, Y188X, G190X, P225H, F227L, or M230L) showed reduced susceptibility to efavirenz in cell culture. Greater than 90% of NRTI-resistant clinical isolates tested in cell culture retained susceptibility to efavirenz.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID124">
               <id root="157c9ee3-48fd-47a6-8603-dc23de86930d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20231213"/>
               <component>
                  <section ID="ID125">
                     <id root="762e47f9-986a-473d-acd9-bb04871b18ab"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID126">Carcinogenesis</paragraph>
                        <paragraph>Long-term carcinogenicity studies in mice and rats were carried out with efavirenz. Mice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of hepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas were increased above background in females. No increases in tumor incidence above background were seen in males. There was no NOAEL in females established for this study because tumor findings occurred at all doses. AUC at the NOAEL (150 mg/kg) in the males was approximately 0.9 times that in humans at the recommended clinical dose. In the rat study, no increases in tumor incidence were observed at doses up to 100 mg/kg/day, for which AUCs were 0.1 (males) or 0.2 (females) times those in humans at the recommended clinical dose.</paragraph>
                        <paragraph>Mutagenesis </paragraph>
                        <paragraph>Efavirenz tested negative in a battery of <content styleCode="italics">in vitro </content>and <content styleCode="italics">in vivo </content>genotoxicity assays. These included bacterial mutation assays in <content styleCode="italics">S. typhimurium </content>and <content styleCode="italics">E. coli</content>, mammalian mutation assays in Chinese hamster ovary cells, chromosome aberration assays in human peripheral blood lymphocytes or Chinese hamster ovary cells, and an <content styleCode="italics">in vivo </content>mouse bone marrow micronucleus assay.</paragraph>
                        <paragraph>Impairment of Fertility</paragraph>
                        <paragraph>Efavirenz did not impair mating or fertility of male or female rats, and did not affect sperm of treated male rats. The reproductive performance of offspring born to female rats given efavirenz was not affected. The AUCs at the NOAEL values in male (200 mg/kg) and female (100 mg/kg) rats were approximately ≤0.15 times that in humans at the recommended clinical dose.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID127">
                     <id root="785d4ce6-acf6-43f6-87bb-f59f5f4b6a53"/>
                     <title>13.3 Animal Toxicology</title>
                     <text>
                        <paragraph ID="ID128">Nonsustained convulsions were observed in 6 of 20 monkeys receiving efavirenz at doses yielding plasma AUC values 4- to13-fold greater than those in humans given the recommended dose<content styleCode="italics"> [see Warnings and Precautions (5.10)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID129">
               <id root="0b0fd531-a65a-4097-b7cb-688236ebd5b5"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20200908"/>
               <component>
                  <section ID="ID130">
                     <id root="8d770b1d-3afa-4877-9a65-7831422e33fd"/>
                     <title>14.1 Adults</title>
                     <text>
                        <paragraph ID="ID131">
                           <content styleCode="bold">Study 006</content>, a randomized, open-label trial, compared Efavirenz (600 mg once daily) + zidovudine (ZDV, 300 mg q12h) + lamivudine (LAM, 150 mg q12h) or Efavirenz (600 mg once daily) + indinavir (IDV, 1000 mg q8h) with indinavir (800 mg q8h) + zidovudine (300 mg q12h) + lamivudine (150 mg q12h). Twelve hundred sixty-six patients (mean age 36.5 years [range 18-81], 60% Caucasian, 83% male) were enrolled. All patients were efavirenz-, lamivudine-, NNRTI-, and PI-naive at study entry. The median baseline CD4+ cell count was 320 cells/mm<sup>3</sup> and the median baseline HIV-1 RNA level was 4.8 log<sub>10</sub> copies/mL. Treatment outcomes with standard assay (assay limit 400 copies/mL) through 48 and 168 weeks are shown in Table 9. Plasma HIV RNA levels were quantified with standard (assay limit 400 copies/mL) and ultrasensitive (assay limit 50 copies/mL) versions of the AMPLICOR HIV-1 MONITOR assay. During the study, version 1.5 of the assay was introduced in Europe to enhance detection of non-clade B virus.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 9: Outcomes of Randomized Treatment Through 48 and 168 Weeks, Study 006</content>
                        </paragraph>
                        <table ID="ID132" width="143%" styleCode="Noautorules">
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> Patients achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Week 48 or Week 168.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Includes patients who rebounded, patients who were on study at Week 48 and failed to achieve confirmed HIV-1 RNA &lt;400 copies/mL at time of discontinuation, and patients who discontinued due to lack of efficacy.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> Includes consent withdrawn, lost to follow-up, noncompliance, never treated, missing data, protocol violation, death, and other reasons. Patients with HIV-1 RNA levels &lt;400 copies/mL who chose not to continue in the voluntary extension phases of the study were censored at date of last dose of study medication.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode=" Toprule Lrule" align="center"> Outcome<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule" align="left"> Efavirenz + ZDV +LAM<br/>              (n=422)<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule" align="center"> Efavirenz + IDV<br/>  (n=429)<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center"> IDV + ZDV + LAM<br/>  (n=415)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule"/>
                                 <td valign="top" styleCode=" Botrule" align="center"> Week 48<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="center"> Week 168<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> Week 48<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> Week 168<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> Week 48<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Week 168<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">  Responder<sup>a</sup>     <br/>
                                 </td>
                                 <td valign="top" align="center"> 69%<br/>
                                 </td>
                                 <td valign="top" align="center"> 48%<br/>
                                 </td>
                                 <td valign="top" align="center"> 57%<br/>
                                 </td>
                                 <td valign="top" align="center"> 40%<br/>
                                 </td>
                                 <td valign="top" align="center"> 50%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 29%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">  Virologic failure<sup>b </sup>  <br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" align="center"> 12%<br/>
                                 </td>
                                 <td valign="top" align="center"> 15%<br/>
                                 </td>
                                 <td valign="top" align="center"> 20%<br/>
                                 </td>
                                 <td valign="top" align="center"> 13%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 19%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left"> Discontinued for<br/>  adverse events<br/>
                                 </td>
                                 <td valign="top" align="center"> 7%<br/>
                                 </td>
                                 <td valign="top" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" align="center"> 6%<br/>
                                 </td>
                                 <td valign="top" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" align="center"> 16%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> 20%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left">  Discontinued for other reasons<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 17%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 31%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 22%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 32%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 21%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 32%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule" align="left">  CD4+ cell count (cells/mm<sup>3</sup>)<br/>  Observed subjects (n)<br/>
                                 </td>
                                 <td valign="top" align="center"> (279)<br/>
                                 </td>
                                 <td valign="top" align="center"> (205)<br/>
                                 </td>
                                 <td valign="top" align="center"> (256)<br/>
                                 </td>
                                 <td valign="top" align="center"> (158)<br/>
                                 </td>
                                 <td valign="top" align="center"> (228)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Rrule" align="center"> (129)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left"> Mean change from baseline<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 190<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 329<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 191<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 319<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 180<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 329<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID133">For patients treated with Efavirenz + zidovudine + lamivudine, Efavirenz + indinavir, or indinavir + zidovudine + lamivudine, the percentage of responders with HIV-1 RNA &lt;50 copies/mL was 65%, 50%, and 45%, respectively, through 48 weeks, and 43%, 31%, and 23%, respectively, through 168 weeks. A Kaplan-Meier analysis of time to loss of virologic response (HIV RNA &lt;400 copies/mL) suggests that both the trends of virologic response and differences in response continue through 4 years.</paragraph>
                        <paragraph>
                           <content styleCode="bold">ACTG 364</content> is a randomized, double-blind, placebo-controlled, 48-week study in NRTI-experienced patients who had completed two prior ACTG studies. One-hundred ninety-six patients (mean age 41 years [range 18-76], 74% Caucasian, 88% male) received NRTIs in combination with Efavirenz (600 mg once daily), or nelfinavir (NFV, 750 mg three times daily), or Efavirenz (600 mg once daily) + nelfinavir in a randomized, double-blinded manner. The mean baseline CD4+ cell count was 389 cells/mm<sup>3</sup> and mean baseline HIV-1 RNA level was 8130 copies/mL. Upon entry into the study, all patients were assigned a new open-label NRTI regimen, which was dependent on their previous NRTI treatment experience. There was no significant difference in the mean CD4+ cell count among treatment groups; the overall mean increase was approximately 100 cells at 48 weeks among patients who continued on study regimens. Treatment outcomes are shown in Table 10. Plasma HIV RNA levels were quantified with the AMPLICOR HIV-1 MONITOR assay using a lower limit of quantification of 500 copies/mL.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 10: Outcomes of Randomized Treatment Through 48 Weeks, Study ACTG 364*</content>
                        </paragraph>
                        <table ID="ID134" width="100%" styleCode="Noautorules">
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">* For some patients, Week 56 data were used to confirm the status at Week 48.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> Subjects achieved virologic response (two consecutive viral loads &lt;500 copies/mL) and maintained it through Week 48.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Includes viral rebound and failure to achieve confirmed &lt;500 copies/mL by Week 48.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> See <content styleCode="italics">Adverse Reactions (6.1) </content>  for a safety profile of these regimens.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>d</sup> Includes loss to follow-up, consent withdrawn, noncompliance.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Toprule Botrule Rrule" align="left"> Outcome<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="center"> Efavirenz + NFV + NRTIs<br/>  (n=65)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="center"> Efavirenz + NRTIs<br/>  (n=65)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center"> NFV + NRTIs<br/>  (n=66)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left">  HIV-1 RNA &lt;500 copies/mL<sup>a</sup>   <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 71%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 63%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 41%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left">  HIV-1 RNA ≥500 copies/mL<sup>b</sup>
                                    <br/>  CDC Category C Event  <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 17%<br/>  2%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 34%<br/>  0%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 54%<br/>  0%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left">  Discontinuations for adverse events<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 3%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left">  Discontinuations for other<br/>  reasons<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 8%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="center"> 0%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID135">A Kaplan-Meier analysis of time to treatment failure through 72 weeks demonstrates a longer duration of virologic suppression (HIV RNA &lt;500 copies/mL) in the Efavirenz-containing treatment arms.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID136">
                     <id root="2357fb4b-a888-4d45-8739-9cdd286cdc39"/>
                     <title>14.2 Pediatric Patients</title>
                     <text>
                        <paragraph ID="ID137">Study AI266922 is an open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of Efavirenz in combination with didanosine and emtricitabine in antiretroviral-naïve and -experienced pediatric patients. Thirty-seven patients 3 months to 6 years of age (median 0.7 years) were treated with Efavirenz. At baseline, median plasma HIV-1 RNA was 5.88 log<sub>10</sub> copies/mL, median CD4+ cell count was 1144 cells/mm<sup>3</sup>, and median CD4+ percentage was 25%. The median time on study therapy was 60 weeks; 27% of patients discontinued before Week 48. Using an ITT analysis, the overall proportions of patients with HIV RNA &lt;400 copies/mL and &lt;50 copies/mL at Week 48 were 57% (21/37) and 46% (17/37), respectively. The median increase from baseline in CD4+ count at 48 weeks was 196 cells/mm<sup>3</sup> and the median increase in CD4+ percentage was 6%. </paragraph>
                        <paragraph>Study PACTG 1021 was an open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of Efavirenz in combination with didanosine and emtricitabine in pediatric patients who were antiretroviral therapy naive. Forty-three patients 3 months to 21 years of age (median 9.6 years) were dosed with Efavirenz. At baseline, median plasma HIV-1 RNA was 4.8 log<sub>10</sub> copies/mL, median CD4+ cell count was 367 cells/mm<sup>3</sup>, and median CD4+ percentage was 18%. The median time on study therapy was 181 weeks; 16% of patients discontinued before Week 48. Using an ITT analysis, the overall proportions of patients with HIV RNA &lt;400 copies/mL and &lt;50 copies/mL at Week 48 were 77% (33/43) and 70% (30/43), respectively. The median increase from baseline in CD4+ count at 48 weeks of therapy was 238 cells/mm<sup>3</sup> and the median increase in CD4+ percentage was 13%.</paragraph>
                        <paragraph>Study PACTG 382 was an open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of Efavirenz in combination with nelfinavir and an NRTI in antiretroviral-naive and NRTI-experienced pediatric patients. One hundred two patients 3 months to 16 years of age (median 5.7 years) were treated with Efavirenz. Eighty-seven percent of patients had received prior antiretroviral therapy. At baseline, median plasma HIV-1 RNA was 4.57 log<sub>10</sub> copies/mL, median CD4+ cell count was 755 cells/mm<sup>3</sup>, and median CD4+ percentage was 30%. The median time on study therapy was 118 weeks; 25% of patients discontinued before Week 48. Using an ITT analysis, the overall proportion of patients with HIV RNA &lt;400 copies/mL and &lt;50 copies/mL at Week 48 were 57% (58/102) and 43% (44/102), respectively. The median increase from baseline in CD4+ count at 48 weeks of therapy was 128 cells/mm<sup>3</sup> and the median increase in CD4+ percentage was 5%.</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID138">
               <id root="bee49227-a260-4ce0-b39c-1bb82432cf4f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20200908"/>
               <component>
                  <section ID="ID139">
                     <id root="493ca0f5-3634-4a5a-9694-12961c5e4860"/>
                     <title>16.2 Tablets</title>
                     <text>
                        <paragraph ID="ID140">Efavirenz tablets USP are available as follows:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Efavirenz Tablets </content>600 mg are off white coloured, capsule shaped, film coated tablets imprinted with "EFZ" on one side and plain on other side. </paragraph>
                        <paragraph>Bottles of 30, NDC – 64380-705-01</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
               <component>
                  <section ID="ID141">
                     <id root="41b3d6b7-e25b-4759-ab69-fdb8b504e013"/>
                     <title>16.3 Storage</title>
                     <text>
                        <paragraph ID="ID142">Efavirenz tablets USP 600 mg should be stored at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F) [See USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20200908"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID143">
               <id root="8e5c53aa-d22b-48e3-b2b8-25fb08b0a864"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID144">Advise the patient to read the FDA-approved patient labeling (Patient Information). </paragraph>
                  <paragraph>Drug Interactions</paragraph>
                  <paragraph>A statement to patients and healthcare providers is included on the product's bottle labels: <content styleCode="italics">ALERT: Find out about medicines that should NOT be taken with Efavirenz.</content>
                  </paragraph>
                  <paragraph>Efavirenz may interact with some drugs; therefore, advise patients to report to their doctor the use of any other prescription or nonprescription medication.</paragraph>
                  <paragraph>General Information for Patients</paragraph>
                  <paragraph>Inform patients that Efavirenz is not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician while taking Efavirenz. </paragraph>
                  <paragraph>Advise patients to avoid doing things that can spread HIV-1 infection to others.</paragraph>
                  <list listType="unordered" ID="ID145" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Do not share or reuse needles or other injection equipment.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Do not have any kind of sex without protection.</content> Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</item>
                     <item>
                        <content styleCode="bold">Do not breastfeed.</content> Mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in breast milk.</item>
                  </list>
                  <paragraph ID="ID146">Dosing Instructions</paragraph>
                  <paragraph>Advise patients to take Efavirenz every day as prescribed. If a patient forgets to take Efavirenz, tell the patient to take the missed dose right away, unless it is almost time for the next dose. Advise the patient not to take 2 doses at one time and to take the next dose at the regularly scheduled time. Advise the patient to ask a healthcare provider if he/she needs help in planning the best times to take his/her medicine.</paragraph>
                  <paragraph>Efavirenz must always be used in combination with other antiretroviral drugs. Advise patients to take Efavirenz on an empty stomach, preferably at bedtime. Taking Efavirenz with food increases efavirenz concentrations and may increase the frequency of adverse reactions. Dosing at bedtime may improve the tolerability of nervous system symptoms <content styleCode="italics">[see Dosage and Administration (2) and Adverse Reactions (6.1)].</content> Healthcare providers should assist parents or caregivers in determining the best Efavirenz dosing schedule for infants and young children.</paragraph>
                  <paragraph>For adult and pediatric patients who cannot swallow capsules or tablets, patients or their caregivers should be advised to read and carefully follow the instructions for administering the capsule contents in a small amount of food or infant formula <content styleCode="italics">[see Dosage and Administration (2.3) and FDA-approved patient labeling (Patient Information)]</content>. Patients should call their healthcare provider or pharmacist if they have any questions. </paragraph>
                  <paragraph>Nervous System Symptoms</paragraph>
                  <paragraph>Inform patients that central nervous system symptoms (NSS) including dizziness, insomnia, impaired concentration, drowsiness, and abnormal dreams are commonly reported during the first weeks of therapy with Efavirenz <content styleCode="italics">[see Warnings and Precautions (5.6)].</content> Dosing at bedtime may improve the tolerability of these symptoms, which are likely to improve with continued therapy. Alert patients to the potential for additive effects when Efavirenz is used concomitantly with alcohol or psychoactive drugs. Instruct patients that if they experience NSS they should avoid potentially hazardous tasks such as driving or operating machinery.</paragraph>
                  <paragraph>Inform patients that there is a risk of developing late-onset neurotoxicity, including ataxia and encephalopathy which may occur months to years after beginning Efavirenz therapy <content styleCode="italics">[see Warnings and Precautions (5.6)]. </content>
                  </paragraph>
                  <paragraph>Psychiatric Symptoms</paragraph>
                  <paragraph>Inform patients that serious psychiatric symptoms including severe depression, suicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms and catatonia have been reported in patients receiving Efavirenz <content styleCode="italics">[see Warnings and Precautions (5.5)]</content>. If they experience severe psychiatric adverse experiences they should seek immediate medical evaluation. Advise patients to inform their physician of any history of mental illness or substance abuse.</paragraph>
                  <paragraph>Rash</paragraph>
                  <paragraph>Inform patients that a common side effect is rash <content styleCode="italics">[see Warnings and Precautions (5.8)].</content> Rashes usually go away without any change in treatment. However, since rash may be serious, advise patients to contact their physician promptly if rash occurs. </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hepatotoxicity </content>
                  </paragraph>
                  <paragraph>Inform patients to watch for early warning signs of liver inflammation or failure, such as fatigue, weakness, lack of appetite, nausea and vomiting, as well as later signs such as jaundice, confusion, abdominal swelling, and discolored feces, and to consult their health care professional without delay if such symptoms occur <content styleCode="italics">[see Warnings and Precautions (5.9) and Adverse Reactions (6.1)].</content>
                  </paragraph>
                  <paragraph>Females of Reproductive Potential</paragraph>
                  <paragraph>Advise females of reproductive potential to use effective contraception as well as a barrier method during treatment with Efavirenz and for 12 weeks after discontinuing Efavirenz. Advise patients to contact their healthcare provider if they plan to become pregnant, or if pregnancy is suspected during treatment with Efavirenz <content styleCode="italics">[see Warnings and Precautions (5.7)</content> <content styleCode="italics">and Use in Specific Populations (8.1, 8.3)].</content>
                  </paragraph>
                  <paragraph>Pregnancy Exposure Registry</paragraph>
                  <paragraph>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Efavirenz during pregnancy <content styleCode="italics">[see Use in Specific Populations (8.1)].</content>
                  </paragraph>
                  <paragraph>Fat Redistribution</paragraph>
                  <paragraph>Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known <content styleCode="italics">[see Warnings and Precautions (5.13)].</content>
                  </paragraph>
                  <paragraph>Manufactured by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Strides Pharma Science Limited</content>
                  </paragraph>
                  <paragraph>Bengaluru-562106, India. </paragraph>
                  <paragraph>Distributed by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Strides Pharma Inc. </content>
                  </paragraph>
                  <paragraph>East Brunswick, NJ 08816.</paragraph>
                  <paragraph>Revision: 12/2023</paragraph>
                  <paragraph>Trademarks are the property of their respective owners.</paragraph>
               </text>
               <effectiveTime value="20231213"/>
            </section>
         </component>
         <component>
            <section ID="ID147">
               <id root="dbe5c98c-f168-4489-b7b1-e99773f63e67"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Information</title>
               <text>
                  <paragraph ID="ID148">
                     <content styleCode="bold">Efavirenz Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(ef" a vir' enz)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: Ask your doctor or pharmacist about medicines that should not be taken with Efavirenz tablets. </content>For more information, see the section "<content styleCode="bold">What should I tell my doctor before taking Efavirenz tablets?</content>" </paragraph>
                  <paragraph>Read this Patient Information before you start taking Efavirenz and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are Efavirenz tablets?</content>
                  </paragraph>
                  <paragraph>Efavirenz is a prescription HIV-1 (Human Immunodeficiency Virus type 1) medicine used with other antiretroviral medicines to treat HIV-1 infection in adults and in children who are at least 3 months old and who weigh at least 7 pounds 12 ounces (3.5 kg). HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome). </paragraph>
                  <paragraph>It is not known if Efavirenz is safe and effective in children younger than 3 months of age or who weigh less than 7 pounds 12 ounces (3.5 kg). </paragraph>
                  <paragraph>When used with other antiretroviral medicines to treat HIV-1 infection, Efavirenz may help:</paragraph>
                  <list listType="unordered" ID="ID149" styleCode="Disc">
                     <item>reduce the amount of HIV-1 in your blood. This is called viral load.</item>
                     <item>increase the number of CD4+ (T) cells in your blood that help fight off other infections.</item>
                  </list>
                  <paragraph ID="ID150">Reducing the amount of HIV-1 and increasing the CD4+ (T) cells in your blood may help improve your immune system. This may reduce your risk of death or getting infections that can happen when your immune system is weak (opportunistic infections).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Efavirenz tablets does not cure HIV-1 infection or AIDS. </content>You should keep taking HIV-1 medicines to control HIV-1 infection and decrease HIV-related illnesses.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoid doing things that can spread HIV-1 infection to others:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID151" styleCode="Disc">
                     <item>Do not share      or reuse needles or other injection equipment.</item>
                     <item>Do not share personal items that can have blood or body fluids      on them, like toothbrushes and razor blades.</item>
                     <item>Do not have any kind of sex without protection. Always practice      safer sex by using a latex or polyurethane condom to lower the chance of      sexual contact with any body fluids such as semen, vaginal secretions, or      blood.</item>
                  </list>
                  <paragraph ID="ID152">Ask your doctor if you have any questions about how to prevent passing HIV to other people.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take Efavirenz tablets? </content>
                  </paragraph>
                  <paragraph>Do not take Efavirenz if you are allergic to efavirenz or any of the ingredients in Efavirenz. See the end of this leaflet for a complete list of ingredients in Efavirenz. </paragraph>
                  <paragraph>Do not take Efavirenz if you are currently taking elbasvir and grazoprevir (ZEPATIER<sup>®</sup>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before taking Efavirenz tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before taking Efavirenz</content> <content styleCode="bold">tablets, tell your doctor if you have any medical conditions and in particular, if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID153" styleCode="Disc">
                     <item>have a heart condition</item>
                     <item>have ever had a mental health problem</item>
                     <item>have ever used street drugs or large      amounts of alcohol</item>
                     <item>have liver problems, including hepatitis      B or C virus infection</item>
                     <item>have a history of seizures</item>
                     <item>are pregnant or plan to become pregnant.      Efavirenz may harm      your unborn baby. If you are able to become      pregnant your healthcare      provider should do a pregnancy test before      you start efavirenz. You should      not become pregnant while taking      Efavirenz and for 12 weeks after stopping      treatment with Efavirenz. <content styleCode="bold">Females      who are able      to become pregnant should use 2 effective forms of birth      control during      treatment and for 12 weeks after stopping treatment      with Efavirenz tablets</content>. A barrier form of birth      control should      always be used along with another type of birth control.</item>
                     <item>Barrier forms of birth control may           include latex or polyurethane condom, contraceptive sponge, diaphragm      with      spermicide, and cervical cap.</item>
                     <item>
                        <content styleCode="bold">Hormonal forms of birth control, such      as birth control pills,      injections, vaginal rings, or implants may      not work during treatment with      Efavirenz tablets</content>.</item>
                     <item>Talk to your doctor about forms of birth      control that may be      used during treatment with Efavirenz.</item>
                     <item>
                        <content styleCode="bold">Pregnancy Registry. </content> There is a      pregnancy registry for women who take      antiretroviral medicines during      pregnancy. The purpose of this      registry is to collect      information about the health of you and your      baby. Talk to your doctor      about how you can take part in this      registry.</item>
                     <item>
                        <content styleCode="bold">Do not breastfeed if you take      Efavirenz tablets.</content>
                     </item>
                     <item>You should not breastfeed if you have HIV      because of the risk of passing      HIV to your baby.</item>
                  </list>
                  <paragraph ID="ID154">
                     <content styleCode="bold">Tell your doctor and pharmacist about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Efavirenz</content> <content styleCode="bold">tablets may affect the way other medicines work, and other medicines may affect how Efavirenz</content> <content styleCode="bold">tablets works</content>, and may cause serious side effects. If you take certain medicines with Efavirenz, the amount of Efavirenz in your body may be too low and it may not work to help control your HIV infection. The HIV virus in your body may become resistant to Efavirenz or other HIV medicines that are like it.</paragraph>
                  <paragraph>
                     <content styleCode="bold">You should not take efavirenz tablets if you take ATRIPLA </content>(efavirenz, emtricitabine, tenofovir disoproxil fumarate) unless your doctor tells you to. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your doctor and pharmacist about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines interact with Efavirenz.</paragraph>
                  <paragraph>Keep a list of your medicines to show your doctor and pharmacist.</paragraph>
                  <list listType="unordered" ID="ID155" styleCode="Disc">
                     <item>You can ask your doctor or pharmacist for a list of medicines      that interact with Efavirenz.</item>
                     <item>
                        <content styleCode="bold">Do not start taking a new medicine without telling your doctor. </content>  Your doctor can tell you if it is safe to take      Efavirenz tablets with other medicines.</item>
                  </list>
                  <paragraph ID="ID156">
                     <content styleCode="bold">How should I take Efavirenz tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID157" styleCode="Disc">
                     <item>Take Efavirenz exactly as your doctor tells you to.</item>
                     <item>Do not change your dose or stop taking Efavirenz unless your      doctor tells you to.</item>
                     <item>Stay under the care of your doctor      during treatment with Efavirenz.</item>
                     <item>Efavirenz must      be used with other antiretroviral medicines.</item>
                     <item>Take Efavirenz      1 time each day.</item>
                     <item>Efavirenz comes as a tablet.</item>
                     <item>Efavirenz tablets must      not be broken.</item>
                     <item>Swallow Efavirenz      whole with liquid.</item>
                  </list>
                  <paragraph ID="ID158">
                     <content styleCode="bold">How and when to take Efavirenz tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID159" styleCode="Disc">
                     <item>You should take Efavirenz on an empty stomach at bedtime. Taking Efavirenz with food increases the amount of medicine in your body. Some side effects may bother you less if you take Efavirenz on an empty stomach and at bedtime.</item>
                     <item>Your child's doctor will prescribe the right dose of Efavirenz based on your child's weight.</item>
                     <item>If you have difficulty swallowing tablets, tell your doctor. Your doctor may recommend opening the efavirenz capsule and mixing the contents with food or infant formula.</item>
                     <item>Adults and children who take efavirenz using the capsule sprinkle method should not eat for 2 hours after taking a dose of efavirenz.</item>
                     <item>Babies should not be given infant formula for 2 hours after taking a dose of efavirenz using the capsule sprinkle method.</item>
                     <item>Do not miss a dose of Efavirenz. If you forget to take Efavirenz, take the missed dose right away, unless it is almost time for your next dose. Do not take 2 doses at one time. Just take your next dose at your regularly scheduled time. If you need help in planning the best times to take your medicine, ask your doctor or pharmacist.</item>
                     <item>If you take too much Efavirenz, call your doctor or go to the nearest hospital emergency room right away.</item>
                     <item>When your efavirenz supply starts to run low, get more from your doctor or pharmacy. It is important not to run out of Efavirenz. The amount of HIV-1 in your blood may increase if the medicine is stopped for even a short time. The virus may become resistant to Efavirenz and harder to treat.</item>
                  </list>
                  <paragraph ID="ID160">
                     <content styleCode="bold">What are the possible side effects of Efavirenz tablets? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Efavirenz tablets may cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID161" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Serious mental health problems </content>  can happen in people who take Efavirenz. Tell your doctor right away if you have any of the following symptoms:<list listType="unordered" styleCode="Circle">
                           <item>feel sad or hopeless</item>
                           <item>feel anxious or restless</item>
                           <item>have thoughts of hurting yourself (suicide) or have tried to hurt yourself or others</item>
                           <item>are not able to tell the difference between what is true or real and what is false or unreal</item>
                           <item>do not trust other people</item>
                           <item>hear or see things that are not real</item>
                           <item>are not able to move or speak normally</item>
                        </list>
                     </item>
                  </list>
                  <list listType="unordered" ID="ID162" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Nervous system symptoms </content>  are common in people who take Efavirenz and can be severe. These symptoms usually begin during the first or second day of treatment with Efavirenz and usually go away after 2 to 4 weeks of treatment. Some symptoms may occur months to years after beginning Efavirenz therapy. These symptoms may become worse if you drink alcohol, take a medicine for mental health problems, or use certain street drugs during treatment with Efavirenz. Symptoms may include:<list listType="unordered" styleCode="Circle">
                           <item>dizziness</item>
                           <item>trouble sleeping</item>
                           <item>trouble concentrating</item>
                           <item>drowsiness</item>
                           <item>unusual dreams</item>
                           <item>lack of coordination or difficulty with balance</item>
                        </list>
                     </item>
                  </list>
                  <paragraph ID="ID163">If you have dizziness, trouble concentrating or drowsiness, do not drive a car, use machinery, or do anything that needs you to be alert.</paragraph>
                  <paragraph>Some nervous system symptoms (e.g., confusion, slow thoughts and physical movement, and delusions [false beliefs] or hallucinations [seeing or hearing things that others do not see or hear]) may occur months to years after beginning Efavirenz therapy. Promptly contact your health care provider should any of these symptoms occur.</paragraph>
                  <list listType="unordered" ID="ID164" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Skin rash </content>  is common with efavirenz but can sometimes be severe. Skin rash usually goes away without any change in treatment. If you develop a rash with any of the following symptoms, tell your doctor right away:<list listType="unordered" styleCode="Circle">
                           <item>skin rash, with or without itching</item>
                           <item>fever</item>
                           <item>swelling of your face</item>
                           <item>blisters or skin lesions</item>
                           <item>peeling skin</item>
                           <item>mouth sores</item>
                           <item>red or inflamed eyes, like "pink eye" (conjunctivitis)</item>
                        </list>
                     </item>
                  </list>
                  <list listType="unordered" ID="ID165" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Liver problems, including liver failure and death </content>  can happen in people who take Efavirenz. Liver problems can happen in people without a history of liver problems. Your doctor will do blood tests to check your liver before you start Efavirenz and during treatment. Tell your doctor right away if you get any of the following symptoms:<list listType="unordered" styleCode="Circle">
                           <item>your skin or the white part of your eyes turns yellow (jaundice)</item>
                           <item>your urine turns dark</item>
                           <item>your bowel movements (stools) turn light in color</item>
                           <item>you don't feel like eating food for several days or longer</item>
                           <item>you feel sick to your stomach (nausea)</item>
                           <item>you have lower stomach area (abdominal) pain</item>
                        </list>
                     </item>
                  </list>
                  <list listType="unordered" ID="ID166" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Seizures </content>  can happen in people who take Efavirenz. Seizures are more likely to happen if you have had seizures in the past. Tell your doctor if you have had a seizure or if you take a medicine to help prevent seizures.</item>
                     <item>
                        <content styleCode="bold">Changes in your immune system (Immune Reconstitution Syndrome) </content>  can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your doctor if you start having new symptoms after starting your HIV-1 medicine.</item>
                     <item>
                        <content styleCode="bold">Changes in body fat </content>  can happen in people who take HIV-1 medicine. These changes may include increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the main part of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known.</item>
                  </list>
                  <paragraph ID="ID167">
                     <content styleCode="bold">The most common side effects of Efavirenz tablets include:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID168" styleCode="Disc">
                     <item>rash</item>
                     <item>dizziness</item>
                     <item>nausea</item>
                     <item>headache</item>
                     <item>difficulty concentrating</item>
                     <item>abnormal dreams</item>
                     <item>tiredness</item>
                     <item>trouble sleeping</item>
                     <item>vomiting</item>
                  </list>
                  <paragraph ID="ID169">Some patients taking Efavirenz have experienced increased levels of lipids (cholesterol and triglycerides) in the blood. Tell your doctor if you have any side effect that bothers you or that does not go away.</paragraph>
                  <paragraph>These are not all the possible side effects of Efavirenz. For more information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to Strides Pharma Inc. at 1-877-244-9825 or go to www.strides.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store Efavirenz tablets?</content>
                  </paragraph>
                  <paragraph>Store Efavirenz tablets at room temperature between 68°F to 77°F (20°C to 25°C).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep Efavirenz tablets and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about Efavirenz tablets</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Efavirenz for a condition for which it was not prescribed. Do not give Efavirenz to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Efavirenz that is written for health professionals. For more information, go to www.strides.com or call 1-877-244-9825.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in Efavirenz tablets? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient: </content>efavirenz </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients: </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Efavirenz tablets: </content>croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coating contains Instacoat Universal/Opacode black Ink. Instacoat Universal contains HPMC 2910/Hypromellose, titanium dioxide, polyethylene glycol, red iron oxide, black iron oxide and yellow iron oxide. Opacode black ink contains propylene glycol, shellac glaze and ferrosoferric oxide.</paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Manufactured by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Strides Pharma Science Limited</content>
                  </paragraph>
                  <paragraph>Bengaluru-562106, India. </paragraph>
                  <paragraph>Distributed by: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Strides Pharma Inc. </content>
                  </paragraph>
                  <paragraph>East Brunswick, NJ 08816.</paragraph>
                  <paragraph>Revision: 12/2023</paragraph>
                  <paragraph>Trademarks are the property of their respective owners.</paragraph>
               </text>
               <effectiveTime value="20231213"/>
            </section>
         </component>
         <component>
            <section ID="ID170">
               <id root="47440932-1768-45f2-a342-39aa882ad7a2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID176">Container Label</paragraph>
                  <paragraph>NDC 64380-705-01</paragraph>
                  <paragraph>Efavirenz tablets USP, 600 mg  Each tablet contains 600 mg of efavirenz.  DOSAGE: For dosage and full prescribing information, read accompanying package insert.  Note to pharmacist: Do not cover ALERT box with pharmacy label.  ALERT: Find out about medicines that should NOT be taken with Efavirenz Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID177">Carton Label</paragraph>
                  <paragraph>NDC 64380-705-01</paragraph>
                  <paragraph>Efavirenz tablets USP, 600 mg  Each tablet contains 600 mg of efavirenz.  DOSAGE: For dosage and full prescribing information, read accompanying package insert.  Note to pharmacist: Do not cover ALERT box with pharmacy label.  ALERT: Find out about medicines that should NOT be taken with Efavirenz Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20210216"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Container label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="b02a7bf3-5dfa-4afe-8093-a2c0250d8798-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="b02a7bf3-5dfa-4afe-8093-a2c0250d8798-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>